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In solid organ transplantation, ischemia/reperfusion (IR) injury during organ procurement, storage and reperfusion is an
unavoidable detrimental event for the graft, as it amplifies graft inflammation and rejection. Intracellular mitogen-activated
protein kinase (MAPK) signaling pathways regulate inflammation and cell survival during IR injury. The four best-characterized
MAPK subfamilies are the c-Jun NH2-terminal kinase (JNK), extracellular signal- regulated kinase-1/2 (ERK1/2), p38 MAPK,
and big MAPK-1 (BMK1/ERK5). Here, we review the role of MAPK activation during myocardial IR injury as it occurs during
heart transplantation. Most of our current knowledge regarding MAPK activation and cardioprotection comes from studies of
preconditioning and postconditioning in nontransplanted hearts. JNK and p38 MAPK activation contributes to myocardial IR
injury after prolonged hypothermic storage. p38 MAPK inhibition improves cardiac function after cold storage, rewarming and
reperfusion. Small-molecule p38 MAPK inhibitors have been tested clinically in patients with chronic inflammatory diseases,
but not in transplanted patients, so far. Organ transplantation oﬀers the opportunity of starting a preconditioning treatment
before organ procurement or during cold storage, thus modulating early events in IR injury. Future studies will need to evaluate
combined strategies including p38 MAPK and/or JNK inhibition, ERK1/2 activation, pre- or postconditioning protocols, new
storage solutions, and gentle reperfusion.
1. Introduction
Heart transplantation is the final therapeutic option for heart
failure [1]. Over the past two decades, advances in immuno-
suppression and antimicrobial agents have improved out-
comes after heart transplantation. An analysis of the UNOS
database in 14,401 first-time orthotopic heart transplant
recipients between the years 1999 and 2006 showed that the
survival rate at 30 days, 1 year, and 5 years was 94%, 87%,
and 75%, respectively, for the young group (<60 years of
age) and 93%, 84%, and 69% for the older group [2]. Graft
vasculopathy, a unique form of accelerated coronary artery
disease, is a major cause of late graft failure [3]. The disease
is characterized by intimal thickening mainly due to smooth
muscle cell proliferation and fibrosis. Occlusive narrowing of
the coronary vessels can develop within a few months and is
not prevented by current treatments.
The pathogenesis of graft vasculopathy is complex and
has been reviewed elsewhere [4–6]. The observation that,
while graft coronary arteries develop lesions, the host’s native
arteries are spared suggests a major pathogenic role for
immune rejection. Consistent with this, while hearts trans-
planted into a genetically diﬀerent recipient are aﬀected,
those placed back in the original donor strain are spared [7].
Clinical data support a major role for chronic rejection in the
development of graft vasculopathy and graft failure. Indeed,
the degree of donor-recipient human leukocyte antigen
(HLA) matching correlates significantly with graft survival
[8–10]. Moreover, acute cellular rejection has been associated
with an increased risk of developing graft vasculopathy
[11–14].
Both the innate [15] and the adaptive immune system
including B cells and antibody formation against graft
antigens [16] play central roles in the development of graft
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vasculopathy. Nonimmunological factors such as dyslipi-
demia, hypertension, drug toxicity, and infections also play
contributory roles. Accordingly, the current paradigm is
that graft vasculopathy results from repeated immune and
nonimmune-mediated insults to graft coronary endothelium
leading to endothelial inflammation and dysfunction, vascu-
lar cell proliferation, fibrosis, and intimal thickening.
Extended cold ischemic times during heart transplanta-
tion have been associated with increased risk of developing
graft vasculopathy and failure both in animal models [17, 18]
and in humans [19]. Moreover, prolonged times between
donor brain death and organ retrieval have been associ-
ated with increased mortality in cardiac transplant recip-
ients [20]. Graft coronary microvascular dysfunction after
ischemia and reperfusion can culminate in primary graft
failure or untreatable chronic rejection [21].
Cold ischemia stimulates the expression of inflammatory
mediators acting as “danger signals” and amplifying tissue
injury and graft rejection. Toll-like receptors (TLRs) play a
central role in this regard [22]. Consistent with this, systemic
administration of anti-TLR-2 antibody reduces neutrophil,
macrophage, and T-lymphocyte infiltration in mouse hearts
after ischemia and reperfusion [23]. Multiple strategies
applied at the time of organ transplantation have a potential
for limiting cold ischemic organ damage, reperfusion injury,
and graft immunogenicity [24, 25].
2. Myocardial Ischemia/Reperfusion (IR) Injury
Early observations in animal models of myocardial infarction
indicated that ischemic cell death progresses as a “wavefront”
phenomenon correlated to the duration of ischemia [26],
and that early reperfusion can salvage reversibly injured
ischemic myocardium [27]. Subsequently, morphological
changes appearing during reperfusion, including cardiomy-
ocyte swelling and loss of sarcomeric organization, were
recognized [28]. Moreover, interventions applied at the onset
of reperfusion were still able to limit infarct size, suggesting a
contributory role for reperfusion in lethal cell injury.
A comprehensive discussion of the molecular mecha-
nisms of myocardial IR injury is beyond the scope of the
present paper. These mechanisms have been reviewed else-
where [29, 30]. It is possible here to briefly mention the
role of mitochondria as both a source and a target of IR
injury [31, 32]. Under normoxic conditions, mitochondria
use oxygen to synthesize adenosine triphosphate (ATP).
Sustained hypoxia leads to ATP depletion, acidosis, intracel-
lular calcium accumulation, mitochondrial swelling, and cell
death [30]. Cold ischemia exacerbates swelling via inhibition
of the Na+/K+ ATPase. At reperfusion, calcium is taken up
into the sarcoplasmic reticulum (SR) by the SR calcium
ATPase. Calcium overload then leads to calcium release into
the cytosol, cardiomyocyte hypercontracture, membrane
disruption, and cell death [30].
During ischemia, mitochondria produce reactive oxygen
species (ROS). An extra burst of ROS generation takes
place at reperfusion. ROS mediates opening of the mito-
chondrial permeability transition pore (MPTP) leading
to increased inner mitochondrial membrane permeability,
mitochondrial depolarization, ATP depletion, mitochondrial
matrix swelling, outer mitochondrial membrane rupture,
cytochrome c release, and apoptosis [30, 32]. In addition,
ROS activates multiple molecular cascades of inflammation
[33]. Proinflammatory cytokines, such as IL-1 and TNFα,
and chemokines are produced within hours of reperfusion
in allogeneic and syngeneic grafts alike. Chemokines mediate
early migration of neutrophils and macrophages into the
graft [34, 35]. Early T-cell reaction precedes alloantigen
priming and induces graft necrosis [36, 37]. Inflammatory
activation of graft endothelium [38], platelets, the coag-
ulation cascade, and the complement system [39] plays
important roles in early graft injury and subsequent graft
vasculopathy.
Amultitude of intracellular signal transduction pathways
are activated during myocardial IR injury [29, 30]. Among
them, mitogen-activated protein kinases (MAPKs) are key
regulators of cell function and survival [40, 41]. The present
paper aims to discuss the role of MAPK activation in
myocardial IR injury and its potential implications for heart
transplantation.
3. MAPK Subfamilies
The MAPK family includes four major serine/threonine
protein kinase subfamilies. Each MAPK subfamily comprises
successively acting kinases including an upstream MAPK
kinase kinase, a MAPK kinase, and a MAPK (Figure 1) [40].
Distinct isoforms of a MAPK bind molecules with diﬀerent
aﬃnities and can activate distinct signaling pathways. In
response to a variety of stress stimuli, MAPKs convey
extracellular signals to their intracellular targets, thereby
regulating cell survival, function, growth, and diﬀerentiation
[41]. The best characterized MAPK subfamilies are c-Jun
NH2-terminal kinases (JNKs), extracellular signal-regulated
kinase-1/2 (ERK1/2, also known as p42/p44 MAPK), p38
MAPKs, and the big MAPK-1 (BMK1/ERK5). The role of
each MAPK subfamily in myocardial IR injury is discussed
in the next sections.
3.1. ERK1/2 Activation during Myocardial IR Injury. ERK1/2
was discovered as the first member of the MAPK family in
1990 [42]. This serine/threonine protein kinase is tyrosine-
phosphorylated in response to various extracellular signals.
We observed a ≈2-fold increase in ERK1/2-specific in vitro
kinase activity in isolated-perfused adult rat hearts subjected
to 20min of ischemia followed by 15min of reperfusion [43].
Several studies support a protective role for the MEK1-ERK2
signaling pathway against IR injury [44–47]. Accordingly,
this pathway has been identified as a central component of
the so-called “Reperfusion Injury Salvage Kinase” (RISK)
pathway [48].
3.2. JNK Activation during Myocardial IR Injury. JNK was
discovered as the second member of the MAPK family in
1991 [49]. It is primarily activated by various cellular stresses
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Figure 1: Schematic depicting the activation cascades of the four major MAPK subfamilies and corresponding eﬀects on mitochondrial
chromosome c release and apoptosis. ERK1/2 and ERK5/BMK1 have been associated with cell survival, whereas JNK and p38 MAPK have
been predominantly associated with apoptosis.
such as heat, UV light, and cytokines. We observed a ≈6-
fold increase in JNK-specific in vitro kinase activity and a
≈2-fold increase in phosphorylated c-Jun protein in nuclear
extracts from isolated-perfused rat hearts subjected to 20min
of ischemia and 15min of reperfusion [43]. JNK activation
was increased during ischemia as well as reperfusion, in line
with a limited number of previous studies [44, 50, 51]. In
contrast, a larger number of studies reported JNK activation
predominantly at reperfusion [52–56].
Dichotomous eﬀects of JNK activation during IR injury
including both cardioprotection [56–59] and myocardial
damage [55, 60–64] have been reported. A potential mech-
anism of JNK-mediated protection is reactivation of Akt and
enhanced cardiomyocyte survival after hypoxic injury [56].
Data in genetically modified mice show that JNK1/2 knock-
out mice and, paradoxically, transgenic mice overexpressing
MKK7, the MAPK kinase upstream of JNK1/2, are each
significantly protected from IR injury [65]. These findings
illustrate the complexity of the biological eﬀects of JNK
activation.
A word of caution is warranted regarding the reliance on
curcumin as a specific JNK inhibitor in early studies [66].
We therefore used a cell-penetrating peptide inhibitor of
JNK, D-JNKI-1, as a more selective agent. In the isolated-
perfused adult rat heart, D-JNKI-1 administered before
the ischemic period selectively prevented JNK activation
and improved post-ischemic cardiac function, cytochrome
c release, caspase-3 activation, and apoptosis [43]. D-JNKI-
1 administered at reperfusion failed to improve cardiac
function but still prevented apoptosis. In vivo, D-JNKI-1
reduced myocardial infarct size by half after coronary artery
occlusion and reperfusion in rats [43]. D-JNKI-1 similarly
reduced cerebral infarct size after common carotid artery
occlusion and reperfusion in adult rats [67].
Inconsistent findings from previous studies regarding the
role of JNK activation during IR injury likely reflect differen-
ces in the experimental models and JNK inhibitors used, as
well as JNK isoform-specific eﬀects. It has been shown that
inhibition of JNK1 isoform, but not of JNK2 isoform, pre-
vents apoptosis induced by IR injury in rat cardiomyocytes
[61].
3.3. p38 MAPK Activation during Myocardial IR Injury. The
p38 MAPK subfamily comprises 4 main isoforms, p38α,
p38β, p38γ, and p38δ, of which p38α and p38γ are most
abundantly expressed within the myocardium. The role
of p38 MAPK activation during myocardial IR remains
controversial [68–70]. We observed a≈2-fold increase in p38
MAPK-specific in vitro kinase activity in isolated-perfused
rat hearts subjected to 20min of ischemia and 15min of
reperfusion [43]. These results are in agreement with pre-
vious data [71]. p38 MAPK activation contributes to tissue
injury induced by TNFα in response to hydrogen peroxide
generated during reperfusion [33]. Moreover, p38 MAPK
activation counteracts adenosine- or insulin-induced cardio-
protection against IR injury [72, 73]. p38 MAPK inhibition
limits infarct size and polymorphonuclear accumulation in
mouse hearts subjected to IR injury [74]. Transgenic mice
expressing a dominant-negative p38αmutant or a dominant-
negative mutant of MKK6, a MAPK kinase upstream of p38
MAPK, are each significantly protected from IR injury [75].
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These data suggest a potential role for p38α isoform as a
mediator of myocardial IR injury.
Much of our current knowledge regarding cardiopro-
tection comes from studies of preconditioning (PC) and
postconditioning (PostC). Although a majority of these
studies relate to nontransplanted hearts, they are relevant to
heart transplantation.
4. Ischemic Preconditioning (IPC)
IPC was originally described as an experimental phe-
nomenon whereby repeated episodes of brief, sublethal
ischemia induced tolerance to a successive, prolonged period
of lethal ischemia [30, 76, 77]. In the anesthetized dog,
four 5 min periods of occlusion of the left coronary artery,
interspersed with 5 min periods of rapid reflow, markedly
attenuated infarct size after occlusion of the same artery for
40min. Two distinct “windows” of IPC-mediated protection
have been described [78, 79]. The first window of protection
is induced within minutes, lasts for 1-2 h, is dependent on
activation of MAPKs as well as of other signaling pathways,
and attenuates infarct size but not contractile dysfunction
nor myocardial stunning. The second window of protection
takes place between 24 and 72 h after the triggering phase
of IPC, requires synthesis of protective proteins within the
heart, and limits cell death as well as contractile dysfunction
[80]. IPC involves changes in energy metabolism, ionic ho-
meostasis, and gene regulation as well as a decrease in
ROS generation, neutrophil activation, and apoptosis [81].
Pharmacological agents such as opioids [82], inhalational
anesthetics [83], adenosine, isoproterenol, and nitric oxide
(NO) donors, [84] along with stress stimuli such as rapid car-
diac pacing and thermal stress can precondition myocardial
tissue to subsequent ischemia [30].
A comprehensive discussion of the molecular mecha-
nisms of IPC is beyond the scope of the present paper.
The interested reader is referred to recent reviews published
elsewhere [30, 77, 85, 86]. It is possible here to merely
mention a few molecular mechanisms. While the triggering
phase of IPC requires NO and superoxide synthesis, IPC
mitigates NO, superoxide, and peroxynitrite overproduction
during subsequent IR [87]. Beside MAPKs, protein kinases
activated by IPC include protein kinase C (PKC) isoforms
[88, 89], phosphatidylinositol 3-kinase (PI3K) and its sub-
strate kinase Akt [90, 91], receptor tyrosine kinases of the Src
family [92, 93], the JAK/STAT pathway [94, 95], and glycogen
synthase-3β (GSK-3β) [96]. The latter is a downstream
kinase phosphorylated by other kinases such as ERK1/2 and
Akt which has been implicated in cardioprotection including
inhibition of MPTP opening at reperfusion. However, recent
data suggest that decreased oxidative stress, rather than
mitochondrial protein phosphorylation, is responsible for
inhibition of MPTP opening in the context of IPC [97].
A number of studies have demonstrated MAPK activa-
tion during the triggering phase of IPC, at reperfusion, or
both. In some cases, IPC has been associated with decreased
MAPK activation during subsequent ischemia, suggesting a
detrimental role for MAPK activation in this context. The
activation of the diﬀerent MAPK subfamilies in precondi-
tioned hearts is discussed in the next sections.
4.1. ERK1/2 Activation during IPC. Both in vitro and in
vivo studies have demonstrated ERK1/2 activation and
cardioprotection after IPC [98–101], which was abolished by
an ERK1/2 inhibitor in a pig model of IR injury [99]. In addi-
tion, hypoxic PC [102, 103] as well as delayed hypoxic PC
[104, 105], adenosine-induced PC [106] as well as adenosine-
induced delayed PC [107], isoflurane/desflurane-induced PC
[83, 108], metabolic PC [109], and opioid-induced delayed
PC are associated with increased ERK1/2 activation [110].
Moreover, mitochondrial KATP channel openers activate
ERK1/2 by an oxidant-dependent mechanism [111].
Several studies reported biphasic ERK1/2 activation
during IPC [82, 83]. The first phase of activation takes
place immediately after the PC stimulus, and the second
phase of activation occurs at reperfusion. Blocking the first
phase of activation prevents the second one [83]. In response
to IPC, PKCε induces the activation of ERK1/2 in the
cytosol and its translocation to the nucleus, with increased
activation of NF-kB and AP-1 transcription factors and
protection against cardiomyocyte apoptosis [101]. Another
mechanism by which ERK1/2 can impart protection to
hypoxic myocardium involves phosphorylation of hypoxia-
inducible factor (HIF)-1 [104].
A small number of studies either reported ERK1/2
activation during IPC [90] or metabolic preconditioning
[112] without a contribution of it to the observed protection,
or failed to detect ERK1/2 activation during IPC [113, 114].
4.2. JNK Activation during IPC. Several studies documented
increased JNK activation during the triggering phase of IPC
[55, 98, 100, 101, 113, 115–117] or, less frequently, during
the sustained ischemic period after the IPC stimulus [113]
or during reperfusion [55, 117]. Some studies suggested
a potential role for JNK as a mediator of IPC-induced
protection [100, 116], but this was not confirmed by other
reports [117, 118]. Decreased JNK activation was observed in
preconditioned brains, kidneys, and hepatocytes [119–121],
suggesting that JNK activation may contribute to IR injury in
these tissues.
4.3. p38 MAPK Activation during IPC. Several studies
reported increased p38 MAPK activation during the trig-
gering phase of IPC and reperfusion [83, 113, 116, 117,
122–132]. A limited number of studies showed p38 MAPK
activation during the sustained ischemic period after the
IPC stimulus [133–135]. p38 MAPK activation has also been
observed in hypoxic PC [136, 137] and delayed hypoxic
PC [138] as well as in NO, [139], angiotensin II [140], or
adenosine-induced PC [115, 141–143].
The role of p38 MAPK as a potential mediator of pro-
tection in the preconditioned heart remains controversial. A
majority of studies showed p38 MAPK activation during the
triggering phase of PC [85, 110, 116, 122, 123, 125, 127–129,
131–138, 140, 141, 143–145]. IPC appears to require p38α
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but not p38β isoform activation [145]. Potential p38 MAPK-
mediated protective mechanisms include phosphorylation of
small heat shock protein (Hsp) 27, which stabilizes the actin
cytoskeleton [146–148], and αβ crystalline [124].
A distinct group of studies failed to support a contrib-
utory role for p38 MAPK activation in IPC [50, 110, 149–
152], hypoxic PC [140, 153], NO-induced PC [154], delayed
metabolic PC [109, 112], and opioid-induced delayed PC
[110]. A third group of studies showed reduced p38 MAPK
activation during the sustained ischemic period after the PC
stimulus [140, 150, 152–154], suggesting a detrimental role
for p38MAPK activation in this setting. Consistent with this,
numerous studies demonstrated that a p38 MAPK inhibitor
applied during the sustained ischemic period can protect the
myocardium against IR injury [44, 116, 125, 126, 140, 147,
149–153, 155, 156].
These inconsistent findings from diﬀerent studies are
diﬃcult to reconcile; however, it should be considered that
the mechanism of p38 MAPK activation can diﬀer by
circumstance [70], and that distinct p38 MAPK isoforms
activate diﬀerent signaling pathways. Increased p38α isoform
activation during sustained ischemia [50, 153] has been
associated with cardiomyocyte apoptosis [157, 158], contrac-
tile dysfunction [158], and increased infarct size [159]. p38
MAPK has been shown to negatively regulate myocardial
contractility [160–162].
4.4. IPC and BMK1/ERK5 Activation. The big MAP kinase
1 (BMK1/ERK5) pathway [163] is activated in the heart in
response to IPC [164] and has been implicated as a potential
mediator of cardioprotection [165]. BMK1/ERK5-induced
phosphorylation of the mitochondrial protein BAD has
been shown to attenuate endothelial cell and cardiomyocyte
apoptosis [166–168]. Similarly, BMK1/ERK5 activation dur-
ing cerebral IPC prevents apoptosis in the ischemic rat
hippocampal CA1 region [169].
5. Remote Preconditioning (RPC)
RPC is a biological mechanism of interorgan protection
against IR injury [170, 171]. Brief cycles of IR applied to
a tissue remote from the heart, such as the small intestine
[172] or the upper or lower limb [173], before the onset
of myocardial ischemia limit myocardial infarct size. A
comparison of RPC and IPC induced by occlusion of the
superior mesenteric artery and the left coronary artery,
respectively, in a rat model of myocardial IR injury showed
a greater eﬀect of IPC compared with RPC in terms of
infarct size reduction [174]. In this study, IPC was associated
with increased ERK1/2 and JNK1 activation but reduced p38
MAPK activation in the heart. In contrast, RPC triggered
by occlusion of the superior mesenteric artery induced
ERK1/2 and JNK1 activation in the small intestine without
participation of MAPKs in the heart. Each of the applied
ERK1/2, JNK, and p38 MAPK inhibitors abrogated RPC-
mediated protection. An underlying mechanism may be
PKCε isoform activation in the heart via remote ischemia-
induced transmitter release [175]. A distinct study showed
equivalent degrees of cardioprotection induced by IPC and
RPC, while suggesting a role for bradykinin as a mediator of
cardiac PC at a distance [176].
6. Postconditioning (PostC)
Ischemic PostC can be elicited by repetitive cycles of rapid
reflow/reocclusion in the initial 2min after release of a
protracted coronary occlusion [29, 30, 177–181]. Because
tissue injury is initiated within minutes of reperfusion, PostC
must be applied at the onset of reperfusion [181]. PostC has
limited infarct size in all species tested so far [177, 178, 182–
184], including humans [185, 186]. The degree of PostC-
mediated cardioprotection is comparable to that induced
by IPC [177, 178, 186], or slightly lower than it [187].
PostC activates adenosine receptors and the NO/cGMP
pathway [188, 189], mitochondrial KATP channels, PKC
and protein kinase G (PKG) [190], and the RISK pathway
including ERK1/2 [188] and PI3K/Akt [184, 189, 191]. In the
rabbit model of myocardial IR injury, an ERK1/2 inhibitor
abolished protection by brief episodes of coronary occlusion
applied at reperfusion [188]. PostC has also been shown to
reduce oxidative stress in a senescent mouse model [192]
and to attenuate cardiomyocyte apoptosis after simulated
ischemia via JNK and p38MAPK inhibition [193].Moreover,
PostC has been shown to inhibit MPTP opening in the early
minutes of reperfusion [194].
The RISK pathway is not the only cardioprotective
pathway [195]. In mouse and rabbit hearts, protection after
ischemic PostC was associated with increased activation
of ERK, but not Akt [183, 196]. In pigs, ischemic PostC
enhanced ERK and Akt activation during reperfusion with-
out a decrease in infarct size [197]. A distinct study in
anesthetized pigs demonstrated myocardial protection after
PostC without an increase in Akt, ERK, and GSK-3β phos-
phorylation and with no eﬀect of PI3K or ERK1/2 blockade
[198]. Gentle reperfusion likewise reduced infarct size in pigs
without activation of the RISK pathway [199]. The so-called
“Survivor Activating Factor Enhancement” (SAFE) pathway
[200] which includes the JAK-STAT signaling pathway [94,
95], may be responsible for cardioprotection in the absence
of activation of the RISK pathway.
Pharmacological stimuli including inhalational anes-
thetics can replace the ischemic PostC stimulus applied
at the onset of reperfusion [201–203]. While myocardial
protection after ischemic PostC is not enhanced by IPC
[187], pharmacological PostC and IPC or pharmacological
PC may have additive eﬀects.
7. IPC, RPC, and PostC for Protection against
Myocardial IR Injury in Humans
Recently, IPC, RPC, and PostC strategies for attenuating
myocardial IR injury have been tested in clinical trials
in nontransplanted patients [77]. Both IPC and phar-
macological PC reduced myocardial IR injury in patients
undergoing coronary artery bypass graft surgery [204–
207]. In a randomized controlled trial, RPC triggered by a
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simple noninvasive technique of four 5 min cycles of lower
limb ischemia and reperfusion induced cardioprotection in
children undergoing cardiac surgery for congenital heart
disease [208]. In a distinct randomized controlled trial, RPC
triggered by transient upper limb ischemia induced car-
dioprotection in adult patients undergoing coronary artery
bypass graft surgery [209]. In the prospective randomized
controlled cardiac remote ischemic preconditioning in coro-
nary stenting (CRISP Stent) trial, RPC alleviated ischemic
chest discomfort and myocardial injury during coronary
stenting, while also reducing subsequent cardiovascular
events [210]. In a randomised trial in patients with acute
myocardial infarction undergoing angioplasty, ischemic RPC
before hospital admission proved to be safe and appeared to
salvage ischemic myocardium [211].
Ischemic PostC has been evaluated in patients with ST
elevation myocardial infarction (STEMI) undergoing angio-
plasty [185]. Within the first minute after stent implantation,
patients in the PostC group underwent four cycles of 1min
inflation and 1min deflation of the coronary angioplasty
balloon. Creatine kinase release, measured as a surrogate for
infarct size, was significantly reduced by 36% in PostC versus
control patients. Contractile function was still improved in
the PostC group at 1 year following infarct [212]. Whether or
not PostC protects against endothelial IR injury in humans
remains unclear [213, 214].
To our knowledge, no data on IPC, RPC, or PostC in
human heart transplantation have been published so far.
Analogously, data on MAPK inhibitors in this setting are
restricted to animal models, as discussed in the next section.
8. MAPK Inhibition in Experimental
Heart Transplantation
ERK1/2, JNK, and p38 MAPK activation within cardiac
grafts has been demonstrated in dogs [215]. MAPK activa-
tion can contribute to graft injury via multiple mechanisms
including cytokine upregulation [216–219], immune cell
activation, and apoptosis.
JNK promotes T-cell activation and diﬀerentiation. For
instance, JNK and ERK1/2 have been shown to stimulate
IL-2 production by Thy-1-activated mouse T lymphocytes
in vitro [220]. JNK inhibition reduced histological rejection
and improved graft survival in a rat model of heart
transplantation [221].
p38 MAPK is involved in IL-2R signaling in T lympho-
cytes, while also stimulating cytokine release from human
macrophages in vitro [222]. A p38 MAPK inhibitor admin-
istered at reperfusion improved functional recovery of rat
hearts after prolonged hypothermic ischemia [223]. In a
brain-dead donor model, a p38MAPK inhibitor lowered sys-
temic levels of proinflammatory cytokines while not aﬀecting
intracardiac cytokine levels [224]. Addition of a p38 MAPK
inhibitor to the Celsior solution enhanced the viability of
cardiac grafts from non-heart-beating donors in a canine
model of heart transplantation [225]. Moreover, p38 MAPK
blockade attenuated the release of proinflammatory IL-6 by
human endothelial cells in vitro after cooling and rewarming
[226]. p38 MAPK inhibition similarly prevented endothe-
lial adhesion molecule expression and polymorphonuclear
accumulation after myocardial IR injury in rats [74]. p38
MAPK blockade markedly reduced vascular smooth muscle
cell proliferation in aortic grafts and the development of
graft vasculopathy [227]. Finally, addition of a p38 MAPK
inhibitor to the Euro-Collins and University of Wisconsin
solutions mitigated IR injury in lung [228] and liver [229]
grafts, respectively, as well as in kidney grafts from non-
heart-beating donors [230]. Thus, a p38 MAPK inhibitor
applied during organ procurement and storage can protect
the graft against IR injury.
9. PC and PostC in Experimental
Heart Transplantation
The potential relevance of PC and PostC strategies to organ
transplantation has been reviewed elsewhere [231–233].
Proof-of-principle studies in animal models have demon-
strated that IPC can impart protection on cardiac grafts
[234–236]. Pretreatment of rat hearts with an adenosine
analog prior to harvesting and storage in the Euro-Collins
solution for 8 hours improved functional recovery at reper-
fusion [237]. In another study, IPC combined with Na+/H+
antiporter inhibition improved cardiac function in rat hearts
after 4 hours of storage at 4◦C in Celsior solution and
extracorporeal reperfusion [238]. KATP channel activation
mimicked the protective eﬀect of IPC in hearts after pro-
longed hypothermic storage [239–241]. However, one study
showed IPC-induced cardioprotection after global ischemia,
but not after cold cardioplegia [242]. Also, brain death
completely abolished PC-mediated protection in ischemic
rabbit hearts [243]. This finding might be explained by
catecholamine storm after brain death, since norepinephrine
injection before IPC abolished protection in the absence of
brain death [244]. AMP-activated protein kinase (AMPK)
is emerging as a target for PC in transplantation medicine
[245].
PC induced by sildenafil administration to the donor
30min before the onset of ischemia improved the function
of cardiac grafts after 3 h of hypothermic cardioplegic arrest
[246]. In contrast, PostC induced by sildenafil administra-
tion 5min before reperfusion in the recipient was ineﬀective.
PKCδ inhibition improved cardiac contractile perfor-
mance and coronary perfusion after cold cardioplegic arrest
in isolated rat hearts [247]. This approach similarly attenu-
ated heart transplant injury and graft coronary vasculopathy
after prolonged organ ischemia [248]. Isoflurane as well as
inhaled hydrogen or carbon monoxide has been shown to
alter energy substrate metabolism to preserve mechanical
function in isolated rat hearts after extended no-flow
hypothermic storage [249, 250].
Ischemic RPC was tested in a pig model of orthotopic
heart transplantation from brain-dead donors [251]. RPC of
the recipient by four 5 min cycles of lower limb ischemia
attenuated IR injury of the denervated donor heart via a KATP
channel-dependent mechanism.
Journal of Transplantation 7
Ischemic PostC was tested in isolated working rat hearts
after global total ischemia (4 h/4◦C) and 45min of reper-
fusion [252]. Three brief episodes of total global ischemia
applied at the onset of reperfusion reducedmyocardial injury
and postischemic dysfunction. In another study, both PostC
and remote PostC attenuated tissue damage in warm
ischemic rat cardiac grafts [253].
The first clinical application of IPC in solid organ trans-
plantation concerned liver transplantation [254]. Although
IPC mitigated inflammatory responses [255], it was associ-
ated with initial poor function. It did neither improve nor
compromise the outcome of cadaver liver transplantation
[254].
10. Concluding Remarks and Perspectives
Proof-of-principle studies have provided evidence that ther-
apeutic manipulation of the donor heart at the time of
transplantation can mitigate graft injury, immunogenicity,
and rejection. A possibility is that molecular events during
the triggering phase of PC, which induce protection, can be
applied to the donor heart before transplantation. A precon-
ditioning drug (e.g., sildenafil) can be administered to the
donor before organ retrieval and/or 5min before reperfusion
in the recipient [246]. The clinical eﬃcacy of ischemic PostC
in STEMI patients [185] suggests that this approach might
be beneficial in heart-transplanted patients as well. A p38
MAPK inhibitor can be added to an organ preservation
solution or administered at reperfusion [223, 225]. A p38
MAPK inhibitor administered to the recipient markedly
inhibited the development of aortic graft vasculopathy in
an experimental model [227]. Small-molecule inhibitors of
p38 MAPK have been developed [256] and tested in initial
clinical trials in patients with active rheumatoid arthritis
or neuropathic pain [257, 258]. Further preclinical studies
are needed, however, before these drugs can be tested
in heart transplant recipients. In principle, extended p38
MAPK inhibitor administration during several weeks or
months after transplantation might protect against graft
vasculopathy.
Because distinct MAPK isoforms have diﬀerent substrate
aﬃnities and functions [61, 145, 159], the precise identifica-
tion of MAPK isoforms that contribute to IR injury would
allow for the development of targeted therapies. Avoiding
indiscriminate MAPK blockade is important because MAPK
activates signaling pathways participating in host defense
against infection and tumors.
Despite promising results obtained with MAPK inhibi-
tors as well as PC and PostC in animal models, it should be
noted that clinical trials of cardioprotective agents success-
fully tested in animal models have been largely negative so far
[259]. However, a recent trial suggested a protective eﬀect of
cyclosporine, a MPTP opening inhibitor, against reperfusion
injury in patients with acute myocardial infarction [260]. In
transplantation medicine, MAPK inhibitors will need to be
tested in combination with other PC and PostC strategies,
as well as with improved organ preservation solutions and
reperfusion protocols (e.g., continuous myocardial perfusion
and controlled initial reperfusion) [261–263].
Acknowledgment
Financial support by the Cecilia-Augusta Foundation,
Lugano, Switzerland, and by the Swiss National Science
Foundation is gratefully acknowledged.
References
[1] M. M. Koerner, J. B. Durand, J. A. Lafuente, G. P. Noon, and
G. Torre-Amione, “Cardiac transplantation: the final ther-
apeutic option for the treatment of heart failure,” Current
Opinion in Cardiology, vol. 15, no. 3, pp. 178–182, 2000.
[2] E. S. Weiss, L. U. Nwakanma, N. D. Patel, and D. D. Yuh,
“Outcomes in patients older than 60 years of age undergoing
orthotopic heart transplantation: an analysis of the UNOS
database,” Journal of Heart and Lung Transplantation, vol. 27,
no. 2, pp. 184–191, 2008.
[3] J. D. Christie, L. B. Edwards, A. Y. Kucheryavaya et al., “The
registry of the international society for heart and lung trans-
plantation: twenty-seventh oﬃcial adult lung and heart-lung
transplant report 2010,” Journal of Heart and Lung Transplan-
tation, vol. 29, no. 10, pp. 1104–1118, 2010.
[4] M. Rahmani, R. P. Cruz, D. J. Granville, and B. M. McManus,
“Allograft vasculopathy versus atherosclerosis,” Circulation
Research, vol. 99, no. 8, pp. 801–815, 2006.
[5] G. Vassalli, A. Gallino, M. Weis et al., “Alloimmunity and
nonimmunologic risk factors in cardiac allograft vasculopa-
thy,” European Heart Journal, vol. 24, no. 13, pp. 1180–1188,
2003.
[6] D. Schmauss and M. Weis, “Cardiac allograft vasculopathy:
recent developments,” Circulation, vol. 117, no. 16, pp. 2131–
2141, 2008.
[7] S. Fiedel, J. Bayer, M. Schaub et al., “The influence of antigen-
dependent and antigen-independent factors on the devel-
opment of graft vasculopathy in a fully allogeneic cardiac
allograft model in the rat,” Transplantation Proceedings, vol.
41, no. 6, pp. 2625–2627, 2009.
[8] J. D. Hosenpud, E. B. Edwards, H. M. Lin, and O. P. Daily,
“Influence of HLA matching on thoracic transplant out-
comes: an analysis from the UNOS/ISHLT thoracic registry,”
Circulation, vol. 94, no. 2, pp. 170–174, 1996.
[9] G. Opelz, T. Wujciak, B. Do¨hler, S. Scherer, and J. Mytilineos,
“HLA compatibility and organ transplant survival. Collabo-
rative Transplant Study,” Reviews in immunogenetics, vol. 1,
no. 3, pp. 334–342, 1999.
[10] I. Kaczmarek, M. A. Deutsch, M. E. Rohrer et al., “HLA-DR
matching improves survival after heart transplantation: is it
time to change allocation policies?” Journal of Heart and Lung
Transplantation, vol. 25, no. 9, pp. 1057–1062, 2006.
[11] J. Jimenez, S. R. Kapadia, M. H. Yamani et al., “Cellular rejec-
tion and rate of progression of transplant vasculopathy: a 3-
year serial intravascular ultrasound study,” Journal of Heart
and Lung Transplantation, vol. 20, no. 4, pp. 393–398, 2001.
[12] M. H. Yamani, M. Yousufuddin, R. C. Starling et al., “Does
acute cellular rejection correlate with cardiac allograft vascu-
lopathy?” Journal of Heart and Lung Transplantation, vol. 23,
no. 3, pp. 272–276, 2004.
[13] H. P. Brunner-La Rocca, J. Schneider, A. Ku¨nzli, M. Turina,
and W. Kiowski, “Cardiac allograft rejection late after
8 Journal of Transplantation
transplantation is a risk factor for graft coronary artery
disease,” Transplantation, vol. 65, no. 4, pp. 538–543, 1998.
[14] M. Dandel, M. Hummel, E. Wellnhofer, S. Kapell, H. B.
Lehmkuhl, and R. Hetzer, “Association between acute rejec-
tion and cardiac allograft vasculopathy,” Journal of Heart and
Lung Transplantation, vol. 22, no. 9, pp. 1064–1065, 2003.
[15] T. M. Millington and J. C. Madsen, “Innate immunity in
heart transplantation,” Current Opinion in Organ Transplan-
tation, vol. 14, no. 5, pp. 571–576, 2009.
[16] A. Gareau, G. M. Hirsch, T. D. G. Lee, and B. Nashan, “Con-
tribution of b cells and antibody to cardiac allograft vascu-
lopathy,” Transplantation, vol. 88, no. 4, pp. 470–477, 2009.
[17] M. Tanaka, G. K. Mokhtari, R. D. Terry et al., “Prolonged
cold ischemia in rat cardiac allografts promotes ischemia-
reperfusion injury and the development of graft coronary
artery disease in a linear fashion,” Journal of Heart and Lung
Transplantation, vol. 24, no. 11, pp. 1906–1914, 2005.
[18] S. Schneeberger, A. Amberger, J. Mandl et al., “Cold ischemia
contributes to the development of chronic rejection and
mitochondrial injury after cardiac transplantation,” Trans-
plant International, vol. 23, no. 12, pp. 1282–1292, 2010.
[19] P. B. Gaudin, B. K. Rayburn, G. M. Hutchins et al., “Per-
itransplant injury to the myocardium associated with the
development of accelerated arteriosclerosis in heart trans-
plant recipients,” American Journal of Surgical Pathology, vol.
18, no. 4, pp. 338–346, 1994.
[20] S. Ramjug, N. Hussain, and N. Yonan, “Prolonged time be-
tween donor brain death and organ retrieval results in an in-
creased risk of mortality in cardiac transplant recipients,”
Interactive Cardiovascular and Thoracic Surgery, vol. 12, no.
6, pp. 938–942, 2011.
[21] R. Tuuminen, S. Syrja¨la¨, R. Krebs et al., “Donor simvastat-
in treatment abolishes rat cardiac allograft ischemia/reperfu-
sion injury and chronic rejection throughmicrovascular pro-
tection,” Circulation, vol. 124, no. 10, pp. 1138–1150, 2011.
[22] D. J. Kaczorowski, A. Nakao, R. Vallabhaneni et al., “Mecha-
nisms of toll-like receptor 4 (TLR4)-mediated inflammation
after cold ischemia/reperfusion in the heart,” Transplanta-
tion, vol. 87, no. 10, pp. 1455–1463, 2009.
[23] F. Arslan, M. B. Smeets, L. A. J. O’Neill et al., “Myocardial is-
chemia/reperfusion injury is mediated by leukocytic toll-like
receptor-2 and reduced by systemic administration of a novel
anti-toll-like receptor-2 antibody,” Circulation, vol. 121, no.
1, pp. 80–90, 2010.
[24] F. J. Van Der Woude, P. Schnuelle, and B. A. Yard, “Precon-
ditioning strategies to limit graft immunogenicity and cold
ischemic organ injury,” Journal of Investigative Medicine, vol.
52, no. 5, pp. 323–329, 2004.
[25] J. Lutz, K. Thu¨rmel, and U. Heemann, “Anti-inflammatory
treatment strategies for ischemia/reperfusion injury in trans-
plantation,” Journal of Inflammation, vol. 7, article 27, 2010.
[26] K. A. Reimer, J. E. Lowe, M. M. Rasmussen, and R. B.
Jennings, “The wavefront phenomenon of ischemic cell
death—1. Myocardial infarct size vs duration of coronary
occlusion in dogs,” Circulation, vol. 56, no. 5, pp. 786–794,
1977.
[27] P. R. Maroko, P. Libby, W. R. Ginks et al., “Coronary artery
reperfusion—I. Early eﬀects on local myocardial function
and the extent of myocardial necrosis,” Journal of Clinical
Investigation, vol. 51, no. 10, pp. 2710–2716, 1972.
[28] R. B. Jennings, H.M. Sommers, G. A. Smyth, H. A. Flack, and
H. Linn, “Myocardial necrosis induced by temporary occlu-
sion of a coronary artery in the dog,” Archives of Pathology,
vol. 70, pp. 68–78, 1960.
[29] D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion
injury,” New England Journal of Medicine, vol. 357, no. 11,
pp. 1121–1135, 2007.
[30] P. Ferdinandy, R. Schulz, and G. F. Baxter, “Interaction
of cardiovascular risk factors with myocardial ischemia/re-
perfusion injury, preconditioning, and postconditioning,”
Pharmacological Reviews, vol. 59, no. 4, pp. 418–458, 2007.
[31] K. Boengler, G. Heusch, and R. Schulz, “Nuclear-encoded
mitochondrial proteins and their role in cardioprotection,”
Biochimica et Biophysica Acta, vol. 1813, no. 7, pp. 1286–1294,
2011.
[32] E. Murphy and C. Steenbergen, “What makes the mitochon-
dria a killer? Can we condition them to be less destructive?”
Biochimica et Biophysica Acta, vol. 1813, no. 7, pp. 1302–1308,
2011.
[33] D. R. Meldrum, C. A. Dinarello, J. C. Cleveland et al., “Hy-
drogen peroxide induces tumor necrosis factor α-mediated
cardiac injury by a P38 mitogen-activated protein kinase-
dependent mechanism,” Surgery, vol. 124, no. 2, pp. 291–297,
1998.
[34] D. Ishii, A. D. Schenk, S. Baba, and R. L. Fairchild, “Role of
TNFα in early chemokine production and leukocyte infiltra-
tion into heart allografts,” American Journal of Transplanta-
tion, vol. 10, no. 1, pp. 59–68, 2010.
[35] J. E. Jordan, Z. Q. Zhao, and J. Vinten-Johansen, “The role
of neutrophils in myocardial ischemia-reperfusion injury,”
Cardiovascular Research, vol. 43, no. 4, pp. 860–878, 1999.
[36] K. Morita, M. Miura, D. R. Paolone et al., “Early chemokine
cascades in murine cardiac grafts regulate T cell recruitment
and progression of acute allograft rejection,” Journal of Im-
munology, vol. 167, no. 5, pp. 2979–2984, 2001.
[37] T. El-Sawy, M. Miura, and R. Fairchild, “Early T cell response
to allografts occuring prior to alloantigen priming up-reg-
ulates innate-mediated inflammation and graft necrosis,”
American Journal of Pathology, vol. 165, no. 1, pp. 147–157,
2004.
[38] B. Mikalsen, B. Fosby, J. Wang et al., “Genome-wide tran-
scription profile of endothelial cells after cardiac transplanta-
tion in the rat,” American Journal of Transplantation, vol. 10,
no. 7, pp. 1534–1544, 2010.
[39] G. M. P. Diepenhorst, T. M. Van Gulik, and C. E. Hack,
“Complement-mediated ischemia-reperfusion injury: les-
sons learned from animal and clinical studies,” Annals of
Surgery, vol. 249, no. 6, pp. 889–899, 2009.
[40] C. Widmann, S. Gibson, M. B. Jarpe, and G. L. Johnson,
“Mitogen-activated protein kinase: conservation of a three-
kinase module from yeast to human,” Physiological Reviews,
vol. 79, no. 1, pp. 143–180, 1999.
[41] N. Gerits, S. Kostenko, and U. Moens, “In vivo functions of
mitogen-activated protein kinases: conclusions from knock-
in and knock-out mice,” Transgenic Research, vol. 16, no. 3,
pp. 281–314, 2007.
[42] T. G. Boulton, G. D. Yancopoulos, J. S. Gregory et al., “An
insulin-stimulated protein kinase similar to yeast kinases
involved in cell cycle control,” Science, vol. 249, no. 4964, pp.
64–67, 1990.
[43] G. Milano, S. Morel, C. Bonny et al., “A peptide inhibitor of
c-Jun NH2-terminal kinase reduces myocardial ischemia-
reperfusion injury and infarct size in vivo,” American Journal
of Physiology, vol. 292, no. 4, pp. H1828–H1835, 2007.
[44] T. L. Yue, C. Wang, J. L. Gu et al., “Inhibition of extracel-
lular signal-regulated kinase enhances ischemia/reoxygena-
tion-induced apoptosis in cultured cardiac myocytes and
Journal of Transplantation 9
exaggerates reperfusion injury in isolated perfused heart,”
Circulation Research, vol. 86, no. 6, pp. 692–699, 2000.
[45] D. J. Lips, O. F. Bueno, B. J. Wilkins et al., “MEK1-ERK2
signaling pathway protects myocardium from ischemic
injury in vivo,” Circulation, vol. 109, no. 16, pp. 1938–1941,
2004.
[46] A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja,
“ERK phosphorylation mediates sildenafil-induced myocar-
dial protection against ischemia-reperfusion injury in mice,”
American Journal of Physiology, vol. 296, no. 5, pp. H1236–
H1243, 2009.
[47] X. Yang, Y. Liu, X.-M. Yang et al., “Cardioprotection by mild
hypothermia during ischemia involves preservation of ERK
activity,” Basic Research in Cardiology, vol. 106, no. 3, pp.
421–430, 2011.
[48] D. J. Hausenloy and D. M. Yellon, “New directions for pro-
tecting the heart against ischaemia-reperfusion injury: tar-
geting the Reperfusion Injury Salvage Kinase (RISK)-path-
way,” Cardiovascular Research, vol. 61, no. 3, pp. 448–460,
2004.
[49] J. M. Kyriakis, P. Banerjee, E. Nikolakaki et al., “The stress-
activated protein kinase subfamily of c-jun kinases,” Nature,
vol. 369, no. 6476, pp. 156–160, 1994.
[50] P. Ping, J. Zhang, S. Huang et al., “PKC-dependent activation
of p46/p54 JNKs during ischemic preconditioning in con-
scious rabbits,” American Journal of Physiology, vol. 277, no.
5, pp. H1771–H1785, 1999.
[51] N. Shimizu, M. Yoshiyama, T. Omura et al., “Activation of
mitogen-activated protein kinases and activator protein- 1 in
myocardial infarction in rats,” Cardiovascular Research, vol.
38, no. 1, pp. 116–124, 1998.
[52] R. J. Knight and D. B. Buxton, “Stimulation of c-Jun kinase
and mitogen-activated protein kinase by ischemia and reper-
fusion in the perfused rat heart,” Biochemical and Biophysical
Research Communications, vol. 218, no. 1, pp. 83–88, 1996.
[53] Y. Mizukami, K. Yoshioka, S. Morimoto, and K. I. Yoshida, “A
novel mechanism of JNK1 activation. Nuclear translocation
and activation of JNK1 during ischemia and reperfusion,”
Journal of Biological Chemistry, vol. 272, no. 26, pp. 16657–
16662, 1997.
[54] T. Yin, G. Sandhu, C. D. Wolfgang et al., “Tissue-specific pat-
tern of stress kinase activation in ischemic/reperfused heart
and kidney,” Journal of Biological Chemistry, vol. 272, no. 32,
pp. 19943–19950, 1997.
[55] R. M. Fryer, H. H. Patel, A. K. Hsu, and G. J. Gross, “Stress-
activated protein kinase phosphorylation during cardiopro-
tection in the ischemic myocardium,” American Journal of
Physiology, vol. 281, no. 3, pp. H1184–H1192, 2001.
[56] Z. Shao, K. Bhattacharya, E. Hsich et al., “c-Jun N-terminal
kinases mediate reactivation of Akt and cardiomyocyte
survival after hypoxic injury in vitro and in vivo,” Circulation
Research, vol. 98, no. 1, pp. 111–118, 2006.
[57] P. Andreka, J. Zang, C. Dougherty, T. I. Slepak, K. A. Webster,
and N. H. Bishopric, “Cytoprotection by Jun kinase during
nitric oxide-induced cardiac myocyte apoptosis,” Circulation
Research, vol. 88, no. 3, pp. 305–312, 2001.
[58] C. J. Dougherty, L. A. Kubasiak, H. Prentice, P. Andreka, N.
H. Bishopric, and K. A. Webster, “Activation of c-Jun N-ter-
minal kinase promotes survival of cardiac myocytes after ox-
idative stress,” Biochemical Journal, vol. 362, no. 3, pp. 561–
571, 2002.
[59] A. M. Engelbrecht, C. Niesler, C. Page, and A. Lochner,
“p38 and JNK have distinct regulatory functions on the
development of apoptosis during simulated ischaemia and
reperfusion in neonatal cardiomyocytes,” Basic Research in
Cardiology, vol. 99, no. 5, pp. 338–350, 2004.
[60] H. Aoki, P. M. Kang, J. Hampe et al., “Direct activation
of mitochondrial apoptosis machinery by c-Jun n-terminal
kinase in adult cardiac myocytes,” Journal of Biological
Chemistry, vol. 277, no. 12, pp. 10244–10250, 2002.
[61] D. Hreniuk, M. Garay, W. Gaarde, B. P. Monia, R. A. Mckay,
and C. L. Cioﬃ, “Inhibition of C-Jun N-terminal kinase
1, but not c-Jun N-terminal kinase 2, suppresses apoptosis
induced by ischemia/reoxygenation in rat cardiac myocytes,”
Molecular Pharmacology, vol. 59, no. 4, pp. 867–874, 2001.
[62] W. G. Li, L. Coppey, R. M. Weiss, and H. J. Oskarsson, “Anti-
oxidant therapy attenuates JNK activation and apoptosis in
the remote noninfarcted myocardium after large myocardial
infarction,” Biochemical and Biophysical Research Communi-
cations, vol. 280, no. 1, pp. 353–357, 2001.
[63] S. H. Kwon, D. R. Pimentel, A. Remondino, D. B. Sawyer, and
W. S. Colucci, “H2O2 regulates cardiac myocyte phenotype
via concentration-dependent activation of distinct kinase
pathways,” Journal of Molecular and Cellular Cardiology, vol.
35, no. 6, pp. 615–621, 2003.
[64] A. Remondino, S. H. Kwon, C. Communal et al., “β-adren-
ergic receptor-stimulated apoptosis in cardiac myocytes is
mediated by reactive oxygen species/c-Jun NH2-terminal
kinase-dependent activation of the mitochondrial pathway,”
Circulation Research, vol. 92, no. 2, pp. 136–138, 2003.
[65] R. A. Kaiser, Q. Liang, O. Bueno et al., “Genetic inhibition or
activation of JNK1/2 protects the myocardium from is-
chemia-reperfusion-induced cell death in vivo,” Journal of
Biological Chemistry, vol. 280, no. 38, pp. 32602–32608, 2005.
[66] Y. R. Chen and T. H. Tan, “Inhibition of the c-Jun N-terminal
kinase (JNK) signaling pathway by curcumin,”Oncogene, vol.
17, no. 2, pp. 173–178, 1998.
[67] T. Borsellol, P. G. H. Clarkel, L. Hirt et al., “A peptide inhibi-
tor of c-Jun N-terminal kinase protects against excitotoxicity
and cerebral ischemia,” Nature Medicine, vol. 9, no. 9, pp.
1180–1186, 2003.
[68] C. Steenbergen, “The role of p38 mitogen-activated protein
kinase in myocardial ischemia/reperfusion injury; Relation-
ship to ischemic preconditioning,” Basic Research in Cardiol-
ogy, vol. 97, no. 4, pp. 276–285, 2002.
[69] P. Ping and E. Murphy, “Role of p38 mitogen-activated
protein kinases in preconditioning: a detrimental factor or
a protective kinase?” Circulation Research, vol. 86, no. 9, pp.
921–922, 2000.
[70] R. Bassi, R. Heads, M. S. Marber, and J. E. Clark, “Targeting
p38-MAPK in the ischaemic heart: kill or cure?” Current
Opinion in Pharmacology, vol. 8, no. 2, pp. 141–146, 2008.
[71] D. Kumar, V. Menon, W. R. Ford, A. S. Clanachan, and B.
I. Jugdutt, “Eﬀect of angiotensin II type 2 receptor blockade
on mitogen activated protein kinase during myocardial
ischemia-reperfusion,” Molecular and Cellular Biochemistry,
vol. 258, no. 1-2, pp. 211–218, 2004.
[72] J. S. Jaswal, M. Gandhi, B. A. Finegan, J. R. B. Dyck, and A.
S. Clanachan, “Inhibition of p38 MAPK and AMPK restores
adenosine-induced cardioprotection in hearts stressed by
antecedent ischemia by altering glucose utilization,” Ameri-
can Journal of Physiology, vol. 293, no. 2, pp. H1107–H1114,
2007.
[73] W. Chai, Y. Wu, G. Li, W. Cao, Z. Yang, and Z. Liu, “Acti-
vation of p38 mitogen-activated protein kinase abolishes
10 Journal of Transplantation
insulin-mediated myocardial protection against ischemia-
reperfusion injury,” American Journal of Physiology-Endocri-
nology and Metabolism, vol. 294, no. 1, pp. E183–E189, 2008.
[74] F. Gao, T. L. Yue, D. W. Shi et al., “p38 MAPK inhibition
reducesmyocardial reperfusion injury via inhibition of endo-
thelial adhesion molecule expression and blockade of PMN
accumulation,” Cardiovascular Research, vol. 53, no. 2, pp.
414–422, 2002.
[75] R. A. Kaiser, O. F. Bueno, D. J. Lips et al., “Targeted inhibition
of p38 mitogen-activated protein kinase antagonizes cardiac
injury and cell death following ischemia-reperfusion in vivo,”
Journal of Biological Chemistry, vol. 279, no. 15, pp. 15524–
15530, 2004.
[76] C. E. Murry, R. B. Jennings, and K. A. Reimer, “Precondi-
tioning with ischemia: a delay of lethal cell injury in ischemic
myocardium,” Circulation, vol. 74, no. 5, pp. 1124–1136,
1986.
[77] A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen, “Protective
ischaemia in patients: preconditioning and postcondition-
ing,” Cardiovascular Research, vol. 83, no. 2, pp. 234–246,
2009.
[78] T. Kuzuya, S. Hoshida, N. Yamashita et al., “Delayed eﬀects of
sublethal ischemia on the acquisition of tolerance to ische-
mia,” Circulation Research, vol. 72, no. 6, pp. 1293–1299,
1993.
[79] M. S. Marber, D. S. Latchman, J. M.Walker, and D.M. Yellon,
“Cardiac stress protein elevation 24 hours after brief ischemia
or heat stress is associated with resistance to myocardial
infarction,” Circulation, vol. 88, no. 3, pp. 1264–1272, 1993.
[80] R. Bolli, Q. H. Li, X. L. Tang et al., “The late phase of precon-
ditioning and its natural clinical application—gene therapy,”
Heart Failure Reviews, vol. 12, no. 3-4, pp. 189–199, 2007.
[81] C. A. Piot, D. Padmanaban, P. C. Ursell, R. E. Sievers, and C.
L. Wolfe, “Ischemic preconditioning decreases apoptosis in
rat hearts in vivo,” Circulation, vol. 96, no. 5, pp. 1598–1604,
1997.
[82] R. M. Fryer, P. F. Pratt, A. K. Hsu, and G. J. Gross, “Dif-
ferential activation of extracellular signal regulated kinase
isoforms in preconditioning and opioid-induced cardiopro-
tection,” Journal of Pharmacology and Experimental Thera-
peutics, vol. 296, no. 2, pp. 642–649, 2001.
[83] R. Da Silva, T. Grampp, T. Pasch, M. C. Schaub, and M.
Zaugg, “Diﬀerential activation of mitogen-activated protein
kinases in ischemic and anesthetic preconditioning,”Anesthe-
siology, vol. 100, no. 1, pp. 59–69, 2004.
[84] R. Bolli, “Cardioprotective function of inducible nitric oxide
synthase and role of nitric oxide in myocardial ischemia and
preconditioning: an overview of a decade of research,” Jour-
nal of Molecular and Cellular Cardiology, vol. 33, no. 11, pp.
1897–1918, 2001.
[85] D. J. Hausenloy, A. Tsang, M. M. Mocanu, and D. M. Yellon,
“Ischemic preconditioning protects by activating prosurvival
kinases at reperfusion,” American Journal of Physiology, vol.
288, no. 2, pp. H971–H976, 2005.
[86] D. J. Hausenloy and D. M. Yellon, “Survival kinases in is-
chemic preconditioning and postconditioning,”Cardiovascu-
lar Research, vol. 70, no. 2, pp. 240–253, 2006.
[87] P. Ferdinandy and R. Schulz, “Nitric oxide, superoxide, and
peroxynitrite in myocardial ischaemia-reperfusion injury
and preconditioning,” British Journal of Pharmacology, vol.
138, no. 4, pp. 532–543, 2003.
[88] Y. Liu, K. Ytrehus, and J. M. Downey, “Evidence that trans-
location of protein kinase C is a key event during ischemic
preconditioning of rabbit myocardium,” Journal of Molecular
and Cellular Cardiology, vol. 26, no. 5, pp. 661–668, 1994.
[89] D. R. Meldrum, J. C. Cleveland, X. Meng et al., “Protein kin-
ase C isoform diversity in preconditioning,” Journal of Surgi-
cal Research, vol. 69, no. 1, pp. 183–187, 1997.
[90] H. Tong, W. Chen, C. Steenbergen, and E. Murphy, “Ischem-
ic preconditioning activates phosphatidylinositol-3-kinase
upstream of protein kinase C,” Circulation Research, vol. 87,
no. 4, pp. 309–315, 2000.
[91] M. M. Mocanu, R. M. Bell, and D. M. Yellon, “PI3 kinase
and not p42/p44 appears to be implicated in the protection
conferred by ischemic preconditioning,” Journal of Molecular
and Cellular Cardiology, vol. 34, no. 6, pp. 661–668, 2002.
[92] C. Vahlhaus, R. Schulz, H. Post, J. Rose, and G. Heusch, “Pre-
vention of ischemic preconditioning only by combined in-
hibition of protein kinase C and protein tyrosine kinase in
pigs,” Journal of Molecular and Cellular Cardiology, vol. 30,
no. 2, pp. 197–209, 1998.
[93] O. Oldenburg, S. D. Critz, M. V. Cohen, and J. M. Downey,
“Acetylcholine-induced production of reactive oxygen spe-
cies in adult rabbit ventricular myocytes is dependent on
phosphatidylinositol 3- and Src-kinase activation and mito-
chondrial KATP channel opening,” Journal of Molecular and
Cellular Cardiology, vol. 35, no. 6, pp. 653–660, 2003.
[94] R. Hattori, N. Maulik, H. Otani et al., “Role of STAT3 in is-
chemic preconditioning,” Journal of Molecular and Cellular
Cardiology, vol. 33, no. 11, pp. 1929–1936, 2001.
[95] S. P. Barry, P. A. Townsend, D. S. Latchman, and A.
Stephanou, “Role of the JAK-STAT pathway in myocardial
injury,” Trends in Molecular Medicine, vol. 13, no. 2, pp. 82–
89, 2007.
[96] M. Juhaszova, D. B. Zorov, S. H. Kim et al., “Glycogen syn-
thase kinase-3β mediates convergence of protection sig-
nalling to inhibit the mitochondrial permeability transition
pore,” Journal of Clinical Investigation, vol. 113, no. 11, pp.
1535–1549, 2004.
[97] S. J. Clarke, I. Khaliulin, M. Das, J. E. Parker, K. J. Heesom,
and A. P. Halestrap, “Inhibition of mitochondrial perme-
ability transition pore opening by ischemic preconditioning
is probably mediated by reduction of oxidative stress rather
than mitochondrial protein phosphorylation,” Circulation
Research, vol. 102, no. 9, pp. 1082–1090, 2008.
[98] P. Ping, J. Zhang, X. Cao et al., “PKC-dependent activation of
p44/p42 MAPKs during myocardial ischemia- reperfusion in
conscious rabbits,” American Journal of Physiology, vol. 276,
no. 5, pp. H1468–H1481, 1999.
[99] C. Strohm, M. Barancik, M. L. V. Bru¨hl, S. A. R. Kilian, and
W. Schaper, “Inhibition of the ER-kinase cascade by PD98059
and UO126 counteracts ischemic preconditioning in pig
myocardium,” Journal of Cardiovascular Pharmacology, vol.
36, no. 2, pp. 218–229, 2000.
[100] C. Strohm, M. Barancı´k, M. L. Von Bruehl et al., “Transcrip-
tion inhibitor actinomycin-D abolishes the cardioprotective
eﬀect of ischemic reconditioning,” Cardiovascular Research,
vol. 55, no. 3, pp. 602–618, 2002.
[101] R. C. X. Li, P. Ping, J. Zhang et al., “PKCε modulates NF-
κB and AP-1 via mitogen-activated protein kinases in adult
rabbit cardiomyocytes,” American Journal of Physiology, vol.
279, no. 4, pp. H1679–H1689, 2000.
[102] L. Button, S. E. Mireylees, R. Germack, and J. M. Dickenson,
“Phosphatidylinositol 3-kinase and ERK1/2 are not involved
in adenosine A1, A2A or A3 receptor-mediated precondition-
ing in rat ventricle strips,” Experimental Physiology, vol. 90,
no. 5, pp. 747–754, 2005.
Journal of Transplantation 11
[103] N. V. Solenkova, V. Solodushko, M. V. Cohen, and J. M.
Downey, “Endogenous adenosine protects preconditioned
heart during early minutes of reperfusion by activating Akt,”
American Journal of Physiology, vol. 290, no. 1, pp. H441–
H449, 2006.
[104] X. Liu, X. Wu, L. Cai, C. Tang, and J. Su, “Hypoxic precondi-
tioning of cardiomyocytes and cardioprotection: phophory-
lation of HIF-1α induced by p42/p44 mitogen-activated pro-
tein kinases is involved,” Pathophysiology, vol. 9, no. 4, pp.
201–205, 2003.
[105] K. Z. Gong, Z. G. Zhang, A. H. Li et al., “ROS-mediated ERK
activation in delayed protection from anoxic preconditioning
in neonatal rat cardiomyocytes,”ChineseMedical Journal, vol.
117, no. 3, pp. 395–400, 2004.
[106] E. A. Reid, G. Kristo, Y. Yoshimura et al., “In vivo adenosine
receptor preconditioning reduces myocardial infarct size via
subcellular ERK signaling,” American Journal of Physiology,
vol. 288, no. 5, pp. H2253–H2259, 2005.
[107] R. D. Lasley, B. J. Keith, G. Kristo, Y. Yoshimura, and R. M.
Mentzer Jr., “Delayed adenosine A1 receptor preconditioning
in rat myocardium is MAPK dependent but iNOS indepen-
dent,” American Journal of Physiology, vol. 289, no. 2, pp.
H785–H791, 2005.
[108] O. Toma, N. C.Weber, J. I. Wolter, D. Obal, B. Preckel, andW.
Schlack, “Desflurane preconditioning induces time-depend-
ent activation of protein kinase C epsilon and extracellular
signal-regulated kinase 1 and 2 in the rat heart in vivo,”
Anesthesiology, vol. 101, no. 6, pp. 1372–1380, 2004.
[109] A. Punn, J. W. Mockridge, S. Farooqui, M. S. Marber, and R.
J. Heads, “Sustained activation of p42/p44 mitogen-activated
protein kinase during recovery from simulated ischaemia
mediates adaptive cytoprotection in cardiomyocytes,” Bio-
chemical Journal, vol. 350, no. 3, pp. 891–899, 2000.
[110] R. M. Fryer, A. K. Hsu, and G. J. Gross, “ERK and p38 MAP
kinase activation are components of opioid-induced delayed
cardioprotection,” Basic Research in Cardiology, vol. 96, no. 2,
pp. 136–142, 2001.
[111] L. Samavati, M. M. Monick, S. Sanlioglu, G. R. Buettner, L.
W. Oberley, and G. W. Hunninghake, “Mitochondrial KATP
channel openers activate the ERK kinase by an oxidant-
dependent mechanism,” American Journal of Physiology, vol.
283, no. 1, pp. C273–C281, 2002.
[112] J. W. Mockridge, A. Punn, D. S. Latchman, M. S. Marber,
and R. J. Heads, “PKC-dependent delayed metabolic pre-
conditioning is independent of transient MAPK activation,”
American Journal of Physiology, vol. 279, no. 2, pp. H492–
H501, 2000.
[113] Y. Takeishi, Q. Huang, T. Wang et al., “Src family kinase and
adenosine diﬀerentially regulate multiple MAP kinases in is-
chemic myocardium: modulation of MAP kinases activation
by ischemic preconditioning,” Journal of Molecular and
Cellular Cardiology, vol. 33, no. 11, pp. 1989–2005, 2001.
[114] S. O. Kim, C. P. Baines, S. D. Critz et al., “Ischemia induced
activation of heat shock protein 27 kinases and casein kinase
2 in the preconditioned rabbit heart,” Biochemistry and Cell
Biology, vol. 77, no. 6, pp. 559–567, 1999.
[115] S. E. A. Haq, A. Clerk, and P. H. Sugden, “Activation of
mitogen-activated protein kinases (p38-MAPKs, SAPKs/
JNKs and ERKs) by adenosine in the perfused rat heart,”
FEBS Letters, vol. 434, no. 3, pp. 305–308, 1998.
[116] M. Sato, G. A. Cordis, N. Maulik, and D. K. Das, “SAPKs reg-
ulation of ischemic preconditioning,” American Journal of
Physiology, vol. 279, no. 3, pp. H901–H907, 2000.
[117] M. Behrends, R. Schulz, H. Post et al., “Inconsistent relation
of MAPK activation to infarct size reduction by ischemic
preconditioning in pigs,” American Journal of Physiology, vol.
279, no. 3, pp. H1111–H1119, 2000.
[118] E. K. Iliodromitis, C. Gaitanaki, A. Lazou et al., “Dissociation
of stress-activated protein kinase (p38-MAPK and JNKs)
phosphorylation from the protective eﬀect of precondition-
ing in vivo,” Journal of Molecular and Cellular Cardiology, vol.
34, no. 8, pp. 1019–1028, 2002.
[119] Z. Gu, Q. Jiang, andG. Zhang, “Extracellular signal-regulated
kinase and c-Jun N-terminal protein kinase in ischemic
tolerance,” NeuroReport, vol. 12, no. 16, pp. 3487–3491, 2001.
[120] D. Crenesse, M. Laurens, J. Gugenheim et al., “Intermit-
tent ischemia reduces warm hypoxia-reoxygenation-induced
JNK1/SAPK1 activation and apoptosis in rat hepatocytes,”
Hepatology, vol. 34, no. 5, pp. 972–978, 2001.
[121] K. M. Park, A. Chen, and J. V. Bonventre, “Prevention of
kidney ischemia/reperfusion-induced functional injury and
JNK, p38, and MAPK kinase activation by remote ischemic
pretreatment,” Journal of Biological Chemistry, vol. 276, no.
15, pp. 11870–11876, 2001.
[122] A. Nakano, C. P. Baines, S. O. Kim et al., “Ischemic pre-
conditioning activates MAPKAPK2 in the isolated rabbit
heart: evidence for involvement of p38 MAPK,” Circulation
Research, vol. 86, no. 2, pp. 144–151, 2000.
[123] K. Sakamoto, T. Urushidani, and T. Nagao, “Translocation
of HSP27 to sarcomere induced by ischemic preconditioning
in isolated rat hearts,” Biochemical and Biophysical Research
Communications, vol. 269, no. 1, pp. 137–142, 2000.
[124] P. Eaton, W. Fuller, J. R. Bell, and M. J. Shattock, “αB crys-
tallin translocation and phosphorylation: signal transduction
pathways and preconditioning in the isolated rat heart,”
Journal of Molecular and Cellular Cardiology, vol. 33, no. 9,
pp. 1659–1671, 2001.
[125] S. Sanada, M. Kitakaze, P. J. Papst et al., “Role of phasic dy-
namism of p38 mitogen-activated protein kinase activation
in ischemic preconditioning of the canine heart,” Circulation
Research, vol. 88, no. 2, pp. 175–180, 2001.
[126] E. Marais, S. Genade, B. Huisamen, J. G. Strijdom, J. A.
Moolman, and A. Lochner, “Activation of p38 MAPK in-
duced by a multi-cycle ischaemic preconditioning protocol
is associated with attenuated p38 MAPK activity during
sustained ischaemia and reperfusion,” Journal of Molecular
and Cellular Cardiology, vol. 33, no. 4, pp. 769–778, 2001.
[127] R. Schulz, S. Belosjorow, P. Gres, J. Jansen, M. C. Michel,
and G. Heusch, “p38 MAP kinase is a mediator of ischemic
preconditioning in pigs,”Cardiovascular Research, vol. 55, no.
3, pp. 690–700, 2002.
[128] R. Schulz, P. Gres, A. Skyschally et al., “Ischemic precondi-
tioning preserves connexin 43 phosphorylation during sus-
tained ischemia in pig hearts in vivo,” The FASEB Journal,
vol. 17, no. 10, pp. 1355–1357, 2003.
[129] Y. Nakamura, T. Miura, A. Nakano et al., “Role of microtu-
bules in ischemic preconditioning against myocardial infarc-
tion,” Cardiovascular Research, vol. 64, no. 2, pp. 322–330,
2004.
[130] E. Marais, S. Genade, R. Salie et al., “The temporal relation-
ship between p38 MAPK and HSP27 activation in ischaemic
and pharmacological preconditioning,” Basic Research in
Cardiology, vol. 100, no. 1, pp. 35–47, 2005.
[131] C. Ballard-Croft, G. Kristo, Y. Yoshimura et al., “Acute adeno-
sine preconditioning is mediated by p38 MAPK activation
in discrete subcellular compartments,” American Journal of
Physiology, vol. 288, no. 3, pp. H1359–H1366, 2005.
12 Journal of Transplantation
[132] J. A. Moolman, S. Hartley, J. Van Wyk, E. Marais, and A.
Lochner, “Inhibition of myocardial apoptosis by ischaemic
and beta-adrenergic preconditioning is dependent on p38
MAPK,” Cardiovascular Drugs and Therapy, vol. 20, no. 1, pp.
13–25, 2006.
[133] C. Weinbrenner, G. S. Liu, M. V. Cohen, and J. M. Downey,
“Phosphorylation of tyrosine 182 of p38 mitogen-activated
protein kinase correlates with the protection of precondi-
tioning in the rabbit heart,” Journal of Molecular and Cellular
Cardiology, vol. 29, no. 9, pp. 2383–2391, 1997.
[134] N. Maulik, M. Sato, B. D. Price, and D. K. Das, “An essential
role of NFκB in tyrosine kinase signaling of p38 MAP kinase
regulation of myocardial adaptation to ischemia,” FEBS Let-
ters, vol. 429, no. 3, pp. 365–369, 1998.
[135] N. Maulik, T. Yoshida, Y. L. Zu, M. Sato, A. Banerjee, and D.
K. Das, “Ischemic preconditioning triggers tyrosine kinase
signaling: a potential role for MAPKAP kinase 2,” American
Journal of Physiology, vol. 275, no. 5, pp. H1857–H1864,
1998.
[136] S. C. Armstrong, M. Delacey, and C. E. Ganote, “Phosphory-
lation state of hsp27 and p38 MAPK during preconditioning
and protein phosphatase inhibitor protection of rabbit car-
diomyocytes,” Journal of Molecular and Cellular Cardiology,
vol. 31, no. 3, pp. 555–567, 1999.
[137] M. Loubani and M. Galin˜anes, “Pharmacological and is-
chemic preconditioning of the human myocardium:
mitoK(ATP) channels are upstream and p38MAPK is down-
stream of PKC,” BMC Physiology, vol. 2, no. 1, article 10, p.
10, 2002.
[138] M. Loubani, A. Hassouna, and M. Galin˜anes, “Delayed pre-
conditioning of the humanmyocardium: signal transduction
and clinical implications,” Cardiovascular Research, vol. 61,
no. 3, pp. 600–609, 2004.
[139] A. Lochner, E. Marais, E. D. U. Toit, and J. Moolman, “Nitric
oxide triggers classic ischemic preconditioning,” Annals of the
New York Academy of Sciences, vol. 962, pp. 402–414, 2002.
[140] S. Kimura, G. X. Zhang, A. Nishiyama et al., “Role of
NAD(P)H oxidase- and mitochondria-derived reactive oxy-
gen species in cardioprotection of ischemic reperfusion inju-
ry by angiotensin II,” Hypertension, vol. 45, no. 5, pp. 860–
866, 2005.
[141] D. S. Nagarkatti and R. I. Sha’afi, “Role of p38 MAP kinase
in myocardial stress,” Journal of Molecular and Cellular
Cardiology, vol. 30, no. 8, pp. 1651–1664, 1998.
[142] A. Dana, M. Skarli, J. Papakrivopoulou, and D. M. Yellon,
“Adenosine A1 receptor induced delayed preconditioning in
rabbits: induction of p38 mitogen-activated protein kinase
activation and Hsp27 phosphorylation via a tyrosine kinase-
and protein kinase C-dependent mechanism,” Circulation
Research, vol. 86, no. 9, pp. 989–997, 2000.
[143] T. C. Zhao, D. S. Hines, and R. C. Kukreja, “Adenosine-in-
duced late preconditioning in mouse hearts: role of p38MAP
kinase and mitochondrial KATP channels,” American Journal
of Physiology, vol. 280, no. 3, pp. H1278–H1285, 2001.
[144] M. M. Mocanu, G. F. Baxter, Y. Yue, S. D. Critz, and D. M.
Yellon, “The p38 MAPK inhibitor, SB203580, abrogates is-
chaemic preconditioning in rat heart but timing of adminis-
tration is critical,” Basic Research in Cardiology, vol. 95, no. 6,
pp. 472–478, 2000.
[145] P. Sicard, J. E. Clark, S. Jacquet et al., “The activation of
p38alpha, and not p38beta, mitogen-activated protein kinase
is required for ischemic preconditioning,” Journal of Molec-
ular and Cellular Cardiology, vol. 48, no. 6, pp. 1324–1328,
2010.
[146] J. Rouse, P. Cohen, S. Trigon et al., “A novel kinase cascade
triggered by stress and heat shock that stimulates MAPKAP
kinase-2 and phosphorylation of the small heat shock
proteins,” Cell, vol. 78, no. 6, pp. 1027–1037, 1994.
[147] G. Li, I. S. Ali, and R.W. Currie, “Insulin-inducedmyocardial
protection in isolated ischemic rat hearts requires p38MAPK
phosphorylation of Hsp27,” American Journal of Physiology,
vol. 294, no. 1, pp. H74–H87, 2008.
[148] R. T. Clements, J. Feng, B. Cordeiro, C. Bianchi, and F. W.
Sellke, “P38 MAPK-dependent small HSP27 and αB-crystal-
lin phosphorylation in regulation of myocardial function fol-
lowing cardioplegic arrest,” American Journal of Physiology,
vol. 300, no. 5, pp. H1669–H1677, 2011.
[149] M. Barancik, P. Htun, C. Strohm, S. Kilian, and W. Schaper,
“Inhibition of the cardiac p38-MAPK pathway by SB203580
delays ischemic cell death,” Journal of Cardiovascular Phar-
macology, vol. 35, no. 3, pp. 474–483, 2000.
[150] A. Gysembergh, B. Z. Simkhovich, R. A. Kloner, and K.
Przyklenk, “p38 MAPK activity is not increased early during
sustained coronary artery occlusion in preconditioned versus
control rabbit heart,” Journal of Molecular and Cellular Car-
diology, vol. 33, no. 4, pp. 681–690, 2001.
[151] S. Schneider, W. Chen, J. Hou, C. Steenbergen, and E. Mur-
phy, “Inhibition of p38 MAPK α/β reduces ischemic injury
and does not block protective eﬀects of preconditioning,”
American Journal of Physiology, vol. 280, no. 2, pp. H499–
H508, 2001.
[152] A. Lochner, S. Genade, S. Hattingh, E. Marais, B. Huisamen,
and J. A. Moolman, “Comparison between Ischaemic and
Anisomycin-Induced Preconditioning: role of p38 MAPK,”
Cardiovascular Drugs and Therapy, vol. 17, no. 3, pp. 217–
230, 2003.
[153] A. T. Saurin, J. L. Martin, R. J. Heads et al., “The role of dif-
ferential activation of p38-mitogen-activated protein kinase
in preconditioned ventricular myocytes,” FASEB Journal, vol.
14, no. 14, pp. 2237–2246, 2000.
[154] R. D. Rakhit, A. N. M. Kabir, J. W. Mockridge, A. Saurin, and
M. S. Marber, “Role of G proteins and modulation of p38
MAPK activation in the protection by nitric oxide against
ischemia-reoxygenation injury,” Biochemical and Biophysical
Research Communications, vol. 286, no. 5, pp. 995–1002,
2001.
[155] K. Mackay and D. Mochly-Rosen, “An inhibitor of p38 mi-
togen-activated protein kinase protects neonatal cardiac
myocytes from ischemia,” Journal of Biological Chemistry, vol.
274, no. 10, pp. 6272–6279, 1999.
[156] X. L. Ma, S. Kumar, F. Gao et al., “Inhibition of p38 mitogen-
activated protein kinase decreases cardiomyocyte apoptosis
and improves cardiac function after myocardial ischemia
and reperfusion,” Circulation, vol. 99, no. 13, pp. 1685–1691,
1999.
[157] S. Nemoto, J. Xiang, S. Huang, and A. Lin, “Induction of
apoptosis by SB202190 through inhibition of p38β mitogen-
activated protein kinase,” Journal of Biological Chemistry, vol.
273, no. 26, pp. 16415–16420, 1998.
[158] Z. Li, Y. M. Jing, I. Kerr et al., “Selective inhibition of p38α
MAPK improves cardiac function and reduces myocardial
apoptosis in rat model of myocardial injury,” American
Journal of Physiology, vol. 291, no. 4, pp. H1972–H1977,
2006.
[159] S. Kumphune, R. Bassi, S. Jacquet et al., “A chemical genet-
ic approach reveals that p38alpha MAPK activation by di-
phosphorylation aggravates myocardial infarction and is
prevented by the direct binding of SB203580,” Journal of
Journal of Transplantation 13
Molecular and Cellular Cardiology, vol. 42, no. 5, pp. 972–980,
2007.
[160] P. Liao, S. Q. Wang, S. Wang et al., “p38 mitogen-activated
protein kinase mediates a negative inotropic eﬀect in cardiac
myocytes,” Circulation Research, vol. 90, no. 2, pp. 190–196,
2002.
[161] F. Chen, H. Kan, G. Hobbs, and M. S. Finkel, “P38 MAP
kinase inhibitor reverses stress-induced myocardial dysfunc-
tion in vivo,” Journal of Applied Physiology, vol. 106, no. 4, pp.
1132–1141, 2009.
[162] I. Szokodi, R. Kerkela¨, A. M. Kubin et al., “Functionally
opposing roles of extracellular signal-regulated kinase 1/2
and p38mitogen-activated protein kinase in the regulation of
cardiac contractility,” Circulation, vol. 118, no. 16, pp. 1651–
1658, 2008.
[163] T. H. Chao, M. Hayashi, R. I. Tapping, Y. Kato, and J. D.
Lee, “MEKK3 directly regulates MEK5 activity as part of the
big mitogen- activated protein kinase 1 (BMK1) signaling
pathway,” Journal of Biological Chemistry, vol. 274, no. 51, pp.
36035–36038, 1999.
[164] Y. Takeishi, J. I. Abe, J. D. Lee, H. Kawakatsu, R. A. Walsh,
and B. C. Berk, “Diﬀerential regulation of p90 ribosomal
S6 kinase and big mitogen- activated protein kinase 1 by
ischemia/reperfusion and oxidative stress in perfused guinea
pig hearts,” Circulation Research, vol. 85, no. 12, pp. 1164–
1172, 1999.
[165] S. J. Cameron, S. Itoh, C. P. Baines et al., “Activation of big
MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after
myocardial ischemia and reperfusion,” FEBS Letters, vol. 566,
no. 1–3, pp. 255–260, 2004.
[166] X. Pi, C. Yan, and B. C. Berk, “Big Mitogen-Activated Protein
Kinase (BMK1)/ERK5 protects endothelial cells from apop-
tosis,” Circulation Research, vol. 94, no. 3, pp. 362–369, 2004.
[167] C. Yan, B. Ding, T. Shishido et al., “Activation of extracellular
signal-regulated kinase 5 reduces cardiac apoptosis and dys-
function via inhibition of a phosphodiesterase 3A/inducible
cAMP early repressor feedback loop,” Circulation Research,
vol. 100, no. 4, pp. 510–519, 2007.
[168] S. H. Qi, Q. H. Guan, M. Wang, and G. Y. Zhang, “Action
of ERK5 in ischemic tolerance suggests its probable partic-
ipation in the signaling mechanism ERK5 in the signaling
mechanism S.-H. Qi et al,” Journal of Receptors and Signal
Transduction, vol. 29, no. 1, pp. 38–43, 2009.
[169] R. M. Wang, Q. G. Zhang, J. Li, L. C. Yang, F. Yang, and D.
W. Brann, “The ERK5-MEF2C transcription factor pathway
contributes to anti-apoptotic eﬀect of cerebral ischemia
preconditioning in the hippocampal CA1 region of rats,”
Brain Research, vol. 1255, pp. 32–41, 2009.
[170] D. J. Hausenloy andD.M. Yellon, “Remote ischaemic precon-
ditioning: underlying mechanisms and clinical application,”
Cardiovascular Research, vol. 79, no. 3, pp. 377–386, 2008.
[171] K. Przyklenk, C. E. Darling, E. W. Dickson, and P. Whittaker,
“Cardioprotection “outside the box”: the evolving paradigm
of remote preconditioning,” Basic Research in Cardiology, vol.
98, no. 3, pp. 149–157, 2003.
[172] B. C. G. Gho, R. G. Schoemaker, M. A. Van den Doel, D. J.
Duncker, and P. D. Verdouw, “Myocardial protection by brief
ischemia in noncardiac tissue,” Circulation, vol. 94, no. 9, pp.
2193–2200, 1996.
[173] R. K. Kharbanda, U. M. Mortensen, P. A. White et al., “Tran-
sient limb ischemia induces remote ischemic preconditioning
in vivo,” Circulation, vol. 106, no. 23, pp. 2881–2883, 2002.
[174] M. Heidbreder, A. Naumann, K. Tempel, P. Dominiak, and A.
Dendorfer, “Remote vs. ischaemic preconditioning: the dif-
ferential role of mitogen-activated protein kinase pathways,”
Cardiovascular Research, vol. 78, no. 1, pp. 108–115, 2008.
[175] S. Wolfrum, K. Schneider, M. Heidbreder, J. Nienstedt, P.
Dominiak, and A. Dendorfer, “Remote preconditioning
protects the heart by activating myocardial PKCε-isoform,”
Cardiovascular Research, vol. 55, no. 3, pp. 583–589, 2002.
[176] R. G. Schoemaker and C. L. vanHeijningen, “Bradykininme-
diates cardiac preconditioning at a distance,” American Jour-
nal of Physiology, vol. 278, no. 5, pp. H1571–H1576, 2000.
[177] Z.-Q. Zhao, J. S. Corvera, M. E. Halkos et al., “Inhibition
of myocardial injury by ischemic postconditioning during
reperfusion: Comparison with ischemic preconditioning,”
American Journal of Physiology, vol. 285, no. 2 54-2, pp.
H579–H588, 2003.
[178] Z. Q. Zhao, J. S. Corvera, M. E. Halkos et al., “Erratum:
Inhibition ofmyocardial injury by ischemic postconditioning
during reperfusion: comparison with ischemic precondition-
ing,” American Journal of Physiology, vol. 286, no. 1, p. H477,
2004.
[179] G. Valen and J. Vaage, “Pre- and postconditioning during car-
diac surgery,” Basic Research in Cardiology, vol. 100, no. 3, pp.
179–186, 2005.
[180] D. M. Yellon and L. H. Opie, “Postconditioning for protec-
tion of the infarcting heart,” Lancet, vol. 367, no. 9509, pp.
456–458, 2006.
[181] M. Ovize, G. F. Baxter, F. Di Lisa et al., “Postconditioning and
protection from reperfusion injury: where do we stand: posi-
tion Paper from theWorking Group of Cellular Biology of the
Heart of the European Society of Cardiology,” Cardiovascular
Research, vol. 87, no. 3, pp. 406–423, 2010.
[182] A. Tsang, D. J. Hausenloy, M. M. Mocanu, and D. M. Yellon,
“Postconditioning: a form of “modified reperfusion” protects
the myocardium by activating the phosphatidylinositol 3-
kinase-Akt pathway,” Circulation Research, vol. 95, no. 3, pp.
230–232, 2004.
[183] C. E. Darling, K. Jiang, M. Maynard, P. Whittaker, J. Vinten-
Johansen, and K. Przyklenk, “Postconditioning via stuttering
reperfusion limits myocardial infarct size in rabbit hearts:
role of ERK1/2,” American Journal of Physiology, vol. 289, no.
4, pp. H1618–H1626, 2005.
[184] E. K. Iliodromitis, M. Georgiadis, M. V. Cohen, J. M.
Downey, E. Bofilis, and D. T. Kremastinos, “Protection from
postconditioning depends on the number of short ischemic
insults in anesthetized pigs,” Basic Research in Cardiology, vol.
101, no. 6, pp. 502–507, 2006.
[185] P. Staat, G. Rioufol, C. Piot et al., “Postconditioning the hu-
man heart,” Circulation, vol. 112, no. 14, pp. 2143–2148,
2005.
[186] C. E. Darling, P. B. Solari, C. S. Smith, M. I. Furman, and K.
Przyklenk, ““Postconditioning” the human heart: multiple
balloon inflations during primary angioplasty may confer
cardioprotection,” Basic Research in Cardiology, vol. 102, no.
3, pp. 274–278, 2007.
[187] M. E. Halkos, F. Kerendi, J. S. Corvera et al., “Myocardial pro-
tection with postconditioning is not enhanced by ischemic
preconditioning,” Annals of Thoracic Surgery, vol. 78, no. 3,
pp. 961–969, 2004.
[188] X. M. Yang, J. B. Proctor, L. Cui, T. Krieg, J. M. Downey,
and M. V. Cohen, “Multiple, brief coronary occlusions
during early reperfusion protect rabbit hearts by targeting
14 Journal of Transplantation
cell signaling pathways,” Journal of the American College of
Cardiology, vol. 44, no. 5, pp. 1103–1110, 2004.
[189] X. M. Yang, S. Philipp, J. M. Downey, and M. V. Cohen,
“Postconditioning’s protection is not dependent on circulat-
ing blood factors or cells but involves adenosine receptors
and requires PI3-kinase and guanylyl cyclase activation,”
Basic Research in Cardiology, vol. 100, no. 1, pp. 57–63, 2005.
[190] D. S. Burley, P. Ferdinandy, and G. F. Baxter, “Cyclic GMP
and protein kinase-G in myocardial ischaemia-reperfusion:
opportunities and obstacles for survival signaling,” British
Journal of Pharmacology, vol. 152, no. 6, pp. 855–869, 2007.
[191] V. Sivaraman, N. R. Mudalgiri, C. Di Salvo et al., “Postcondi-
tioning protects human atrial muscle through the activation
of the RISK pathway,” Basic Research in Cardiology, vol. 102,
no. 5, pp. 453–459, 2007.
[192] B. Lauzier, S. Delemasure, R. Debin et al., “Beneficial eﬀects
of myocardial postconditioning are associated with reduced
oxidative stress in a senescent mouse model,” Transplanta-
tion, vol. 85, no. 12, pp. 1802–1808, 2008.
[193] H. Y. Sun, N. P. Wang, M. Halkos et al., “Postconditioning
attenuates cardiomyocyte apoptosis via inhibition of JNK
and p38 mitogen-activated protein kinase signaling path-
ways,” Apoptosis, vol. 11, no. 9, pp. 1583–1593, 2006.
[194] M. V. Cohen, X. M. Yang, and J. M. Downey, “Acidosis, oxy-
gen, and interference with mitochondrial permeability tran-
sition pore formation in the early minutes of reperfusion
are critical to postconditioning’s success,” Basic Research in
Cardiology, vol. 103, no. 5, pp. 464–471, 2008.
[195] G. Heusch, “No RISK, no...cardioprotection? A critical per-
spective,”Cardiovascular Research, vol. 84, no. 2, pp. 173–175,
2009.
[196] K. Przyklenk, M. Maynard, C. E. Darling, and P. Whittaker,
“Aging mouse hearts are refractory to infarct size reduction
with post-conditioning,” Journal of the American College of
Cardiology, vol. 51, no. 14, pp. 1393–1398, 2008.
[197] L. M. Schwartz and C. J. Lagranha, “Ischemic postcondition-
ing during reperfusion activates Akt and ERK without pro-
tecting against lethal myocardial ischemia-reperfusion injury
in pigs,” American Journal of Physiology, vol. 290, no. 3, pp.
H1011–H1018, 2006.
[198] A. Skyschally, P. van Caster, K. Boengler et al., “Ischemic
postconditioning in pigs: no causal role for risk activation,”
Circulation Research, vol. 104, no. 1, pp. 15–18, 2009.
[199] J. Musiolik, P. Van Caster, A. Skyschally et al., “Reduction of
infarct size by gentle reperfusion without activation of re-
perfusion injury salvage kinases in pigs,” Cardiovascular
Research, vol. 85, no. 1, pp. 110–117, 2010.
[200] S. Lecour, “Activation of the protective Survivor Activating
Factor Enhancement (SAFE) pathway against reperfusion
injury: does it go beyond the RISK pathway?” Journal of
Molecular and Cellular Cardiology, vol. 47, no. 1, pp. 32–40,
2009.
[201] P. C. Chiari, M. W. Bienengraeber, P. S. Pagel, J. G.
Krolikowski, J. R. Kersten, and D. C. Warltier, “Isoflurane
protects against myocardial infarction during early reper-
fusion by activation of phosphatidylinositol-3-kinase signal
transduction: evidence for anesthetic-induced postcondi-
tioning in rabbits,” Anesthesiology, vol. 102, no. 1, pp. 102–
109, 2005.
[202] D. Tessier-Vetzel, R. Tissier, X. Waintraub, B. Ghaleh, and
A. Berdeaux, “Isoflurane inhaled at the onset of reperfusion
potentiates the cardioprotective eﬀect of ischemic postcon-
ditioning through a NO-dependent mechanism,” Journal of
Cardiovascular Pharmacology, vol. 47, no. 3, pp. 487–492,
2006.
[203] D. Obal, S. Dettwiler, C. Favoccia, H. Scharbatke, B. Preckel,
and W. Schlack, “The influence of mitochondrial KATP-
channels in the cardioprotection of preconditioning and
postconditioning by sevoflurane in the rat in vivo,”Anesthesia
and Analgesia, vol. 101, no. 5, pp. 1252–1260, 2005.
[204] D. M. Yellon, A. M. Alkhulaifi, and W. B. Pugsley, “Precondi-
tioning the human myocardium,” Lancet, vol. 342, no. 8866,
pp. 276–277, 1993.
[205] D. P. Jenkins, W. B. Pugsley, A. M. Alkhulaifi, M. Kemp,
J. Hooper, and D. M. Yellon, “Ischaemic preconditioning
reduces troponin T release in patients undergoing coronary
artery bypass surgery,” Heart, vol. 77, no. 4, pp. 314–318,
1997.
[206] E. X. Lu, S. X. Chen, M. D. Yuan et al., “Preconditioning
improves myocardial preservation in patients undergoing
open heart operations,” Annals of Thoracic Surgery, vol. 64,
no. 5, pp. 1320–1324, 1997.
[207] L. K. Teoh, R. Grant, J. A. Hulf, W. B. Pugsley, and D. M.
Yellon, “The eﬀect of preconditioning (ischemic and phar-
macological) on myocardial necrosis following coronary
artery bypass graft surgery,” Cardiovascular Research, vol. 53,
no. 1, pp. 175–180, 2002.
[208] M. M. H. Cheung, R. K. Kharbanda, I. E. Konstantinov et
al., “Randomized controlled trial of the eﬀects of remote
ischemic preconditioning on children undergoing cardiac
surgery. First clinical application in humans,” Journal of the
American College of Cardiology, vol. 47, no. 11, pp. 2277–
2282, 2006.
[209] D. J. Hausenloy, P. K. Mwamure, V. Venugopal et al., “Eﬀect
of remote ischaemic preconditioning on myocardial injury
in patients undergoing coronary artery bypass graft surgery:
a randomised controlled trial,” Lancet, vol. 370, no. 9587, pp.
575–579, 2007.
[210] S. P. Hoole, P. M. Heck, L. Sharples et al., “Cardiac remote
ischemic preconditioning in coronary stenting (CRISP stent)
study. A prospective, randomized control trial,” Circulation,
vol. 119, no. 6, pp. 820–827, 2009.
[211] H. E. Bøtker, R. Kharbanda, M. R. Schmidt et al., “Remote
ischaemic conditioning before hospital admission, as a
complement to angioplasty, and eﬀect on myocardial salvage
in patients with acute myocardial infarction: a randomised
trial,” The Lancet, vol. 375, no. 9716, pp. 727–734, 2010.
[212] H. Thibault, C. Piot, P. Staat et al., “Long-term benefit of
postconditioning,” Circulation, vol. 117, no. 8, pp. 1037–
1044, 2008.
[213] S. P. Loukogeorgakis, A. T. Panagiotidou, D. M. Yellon, J. E.
Deanfield, and R. J. MacAllister, “Postconditioning pro-
tects against endothelial ischemia-reperfusion injury in the
human forearm,” Circulation, vol. 113, no. 7, pp. 1015–1019,
2006.
[214] S. Dragoni, G. Di Stolfo, S. Sicuro et al., “Postconditioning
fails to prevent radial artery endothelial dysfunction induced
by ischemia and reperfusion: evidence from a human in vivo
study,” Canadian Journal of Physiology and Pharmacology,
vol. 84, no. 6, pp. 611–615, 2006.
[215] N. Koike, I. Takeyoshi, S. Ohki, M. Tokumine, and Y.
Morishita, “The comparison of mitogen-activated protein
kinases that become activated within the left ventricular and
right atrial tissues following heart transplantation in canine
model,” Journal of Investigative Surgery, vol. 20, no. 2, pp.
105–111, 2007.
Journal of Transplantation 15
[216] C. Ballard-Croft, D. J. White, D. L. Maass, D. P. Hybki, and
J. W. Horton, “Role of p38 mitogen-activated protein kinase
in cardiac myocyte secretion of the inflammatory cytokine
TNF-α,” American Journal of Physiology, vol. 280, no. 5, pp.
H1970–H1981, 2001.
[217] M. Li, D. Georgakopoulos, G. Lu et al., “p38 MAP kinase
mediates inflammatory cytokine induction in cardiomy-
ocytes and extracellular matrix remodeling in heart,” Circu-
lation, vol. 111, no. 19, pp. 2494–2502, 2005.
[218] M. Bellahcene, S. Jacquet, X. B. Cao et al., “Activation of
p38 mitogen-activated protein kinase contributes to the early
cardiodepressant action of tumor necrosis factor,” Journal of
the American College of Cardiology, vol. 48, no. 3, pp. 545–
555, 2006.
[219] H. Yin, J. Zhang, H. Lin et al., “p38mitogen-activated protein
kinase inhibition decreases TNFalpha secretion and protects
against left ventricular remodeling in rats with myocardial
ischemia,” Inflammation, vol. 31, no. 2, pp. 65–73, 2008.
[220] D. M. Conrad, S. J. Furlong, C. D. Doucette, R. T. M.
Boudreau, and D. W. Hoskin, “Role of mitogen-activated
protein kinases in Thy-1-induced T-lymphocyte activation,”
Cellular Signalling, vol. 21, no. 8, pp. 1298–1307, 2009.
[221] A. Tabata, M. Morikawa, M. Miyajima et al., “Suppression
of alloreactivity and allograft rejection by SP600125, a small
molecule inhibitor of c-Jun N-terminal kinase,” Transplanta-
tion, vol. 83, no. 10, pp. 1358–1364, 2007.
[222] S. J. Smith, P. S. Fenwick, A. G. Nicholson et al., “Inhibitory
eﬀect of p38 mitogen-activated protein kinase inhibitors on
cytokine release from human macrophages,” British Journal
of Pharmacology, vol. 149, no. 4, pp. 393–404, 2006.
[223] A. S. Clanachan, J. S. Jaswal, M. Gandhi et al., “Eﬀects of
inhibition of myocardial extracellular-responsive kinase and
p38 mitogen-activated protein kinase on mechanical func-
tion of rat hearts after prolonged hypothermic ischemia,”
Transplantation, vol. 75, no. 2, pp. 173–180, 2003.
[224] T. Oto, A. Calderone, Z. Li, F. L. Rosenfeldt, and S. Pepe,
“p38 Mitogen-activated protein kinase inhibition reduces
inflammatory cytokines in a brain-dead transplant donor
animal model.,” Heart, lung & circulation, vol. 18, no. 6, pp.
393–400, 2009.
[225] N. Koike, I. Takeyoshi, S. Ohki, M. Tokumine, K.Matsumoto,
and Y. Morishita, “Eﬀects of adding p38 mitogen-activated
protein-kinase inhibitor to celsior solution in canine heart
transplantation from non-heart-beating donors,” Transplan-
tation, vol. 77, no. 2, pp. 286–292, 2004.
[226] A. Diestel, J. Roessler, A. Pohl-Schickinger et al., “Specific p38
inhibition in stimulated endothelial cells: a possible new anti-
inflammatory strategy after hypothermia and rewarming,”
Vascular Pharmacology, vol. 51, no. 4, pp. 246–252, 2009.
[227] R. O¨llinger, M. Thomas, P. Kogler et al., “Blockade of p38
MAPK inhibits chronic allograft vasculopathy,” Transplanta-
tion, vol. 85, no. 2, pp. 293–297, 2008.
[228] N. Hashimoto, I. Takeyoshi, D. Yoshinari et al., “Eﬀects of a
p38 mitogen-activated protein kinase inhibitor as an additive
to euro-collins solution on reperfusion injury in canine lung
transplantation,” Transplantation, vol. 74, no. 3, pp. 320–326,
2002.
[229] D. Yoshinari, I. Takeyoshi, M. Kobayashi et al., “Eﬀects of a
p38 mitogen-activated protein kinase inhibitor as an additive
to University of Wisconsin solution on reperfusion injury in
liver transplantation,” Transplantation, vol. 72, no. 1, pp. 22–
27, 2001.
[230] C. Doucet, S. Milin, F. Favreau et al., “A p38 mitogen-activat-
ed protein kinase inhibitor protects against renal damage
in a non-heart-beating donor model,” American Journal of
Physiology, vol. 295, no. 1, pp. F179–F191, 2008.
[231] M. Kosieradzki, “Mechanisms of ischemic preconditioning
and its application in transplantation,” Annals of Transplan-
tation, vol. 7, no. 3, pp. 12–20, 2002.
[232] J. T. Ambros, I. Herrero-Fresneda, O. G. Borau, and J. M. G.
Boira, “Ischemic preconditioning in solid organ transplanta-
tion: from experimental to clinics,” Transplant International,
vol. 20, no. 3, pp. 219–229, 2007.
[233] N. Selzner, M. Boehnert, and M. Selzner, “Preconditioning,
postconditioning, and remote conditioning in solid organ
transplantation: basic mechanisms and translational applica-
tions,” Transplantation Reviews. In press.
[234] M. Karck, P. Rahmanian, and A. Haverich, “Ischemic precon-
ditioning enhances donor heart preservation,” Transplanta-
tion, vol. 62, no. 1, pp. 17–22, 1996.
[235] J. T. Cope, M. C. Mauney, D. Banks et al., “Intravenous phe-
nylephrine preconditioning of cardiac grafts from non-
heart-beating donors,”Annals of Thoracic Surgery, vol. 63, no.
6, pp. 1664–1668, 1997.
[236] R. W. Landymore, A. J. Bayes, J. T. Murphy, and J. H. Fris,
“Preconditioning prevents myocardial stunning after cardiac
transplantation,” Annals of Thoracic Surgery, vol. 66, no. 6,
pp. 1953–1957, 1998.
[237] I. Ahmet, Y. Sawa, M. Nishimura, M. Kitakaze, and H. Mat-
suda, “Cardioprotective eﬀect of diadenosine tetraphosphate
(AP4A) preservation in hypothermic storage and its relation
with mitochondrial ATP- sensitive potassium channels,”
Transplantation, vol. 69, no. 1, pp. 16–20, 2000.
[238] E. Kevelaitis, A. Oube´naissa, C. Mouas, J. Peynet, and P.
Menasche´, “Ischemic preconditioning with opening of mito-
chondrial adenosine triphosphate-sensitive potassium chan-
nels or Na+/H+ exchange inhibition: which is the best
protective strategy for heart transplants?” Journal of Thoracic
and Cardiovascular Surgery, vol. 121, no. 1, pp. 155–162,
2001.
[239] E. Kevelaitis, A. Oube´naı¨ssa, J. Peynet, C. Mouas, and P.
Menasche´, “Preconditioning by mitochondrial ATP-sensitive
potassium channel openers: an eﬀective approach for im-
proving the preservation of heart transplants,” Circulation,
vol. 100, no. 19, supplement, pp. II345–II350, 1999.
[240] M. Hicks, Z. Y. Du, P. Jansz, S. Rainer, P. Spratt, and P. S. Mac-
donald, “ATP-sensitive potassium channel activation mimics
the protective eﬀect of ischaemic preconditioning in the rat
isolated working heart after prolonged hypothermic storage,”
Clinical and Experimental Pharmacology and Physiology, vol.
26, no. 1, pp. 20–25, 1999.
[241] E. Kevelaitis, J. Peynet, C. Mouas, J. M. Launay, and P.
Menasche´, “Opening of potassium channels the common
cardioprotective link between preconditioning and natural
hibernation?” Circulation, vol. 99, no. 23, pp. 3079–3085,
1999.
[242] G. Valen, S. Takeshima, and J. Vaage, “Preconditioning im-
proves cardiac function after global ischemia, but not after
cold cardioplegia,” Annals of Thoracic Surgery, vol. 62, no. 5,
pp. 1397–1403, 1996.
[243] M. Kirsch, F. Farhat, J. P. Garnier, and D. Loisance, “Acute
brain death abolishes the cardioprotective eﬀects of ischemic
preconditioning in the rabbit,” Transplantation, vol. 69, no.
10, pp. 2013–2019, 2000.
[244] F. Farhat, D. Loisance, J. P. Garnier, and M. Kirsch, “Norepi-
nephrine release after acute brain death abolishes the car-
dioprotective eﬀects of ischemic preconditioning in rabbit,”
16 Journal of Transplantation
European Journal of Cardio-thoracic Surgery, vol. 19, no. 3,
pp. 313–320, 2001.
[245] H. R. Bouma, M. E. Ketelaar, B. A. Yard, R. J. Ploeg, and R. H.
Henning, “AMP-activated protein kinase as a target for pre-
conditioning in transplantation medicine,” Transplantation,
vol. 90, no. 4, pp. 353–358, 2010.
[246] P. Botha, G. A. MacGowan, and J. H. Dark, “Sildenafil citrate
augments myocardial protection in heart transplantation,”
Transplantation, vol. 89, no. 2, pp. 169–177, 2010.
[247] R. T. Clements, B. Cordeiro, J. Feng, C. Bianchi, and F. W.
Sellke, “Rottlerin increases cardiac contractile performance
and coronary perfusion through BKca++ channel activation
after cold cardioplegic arrest in isolated hearts,” Circulation,
vol. 124, no. 11, supplement 1, pp. S55–S61, 2011.
[248] M. Tanaka, F. Gunawan, R. D. Terry et al., “Inhibition of
heart transplant injury and graft coronary artery disease
after prolonged organ ischemia by selective protein kinase C
regulators,” Journal of Thoracic and Cardiovascular Surgery,
vol. 129, no. 5, pp. 1160–1167, 2005.
[249] B. A. Finegan, M. Gandhi, M. R. Cohen, D. Legatt, and A. S.
Clanachan, “Isoflurane alters energy substrate metabolism to
preserve mechanical function in isolated rat hearts following
prolonged no-flow hypothermic storage,” Anesthesiology, vol.
98, no. 2, pp. 379–386, 2003.
[250] A. Nakao, D. J. Kaczorowski, Y. Wang et al., “Amelioration
of rat cardiac cold ischemia/reperfusion injury with inhaled
hydrogen or carbonmonoxide, or both,” Journal of Heart and
Lung Transplantation, vol. 29, no. 5, pp. 544–553, 2010.
[251] I. E. Konstantinov, J. Li, M. M. Cheung et al., “Remote
ischemic preconditioning of the recipient reduces myocardial
ischemia-reperfusion injury of the denervated donor heart
via a Katp channel-dependent mechanism,” Transplantation,
vol. 79, no. 12, pp. 1691–1695, 2005.
[252] B. Lauzier, P. Sicard, O. Bouchot et al., “After four hours of
cold ischemia and cardioplegic protocol, the heart can still be
rescued with postconditioning,” Transplantation, vol. 84, no.
11, pp. 1474–1482, 2007.
[253] Y. Tang, A. Mennander, N. Oksala et al., “Postconditioning
and remote postconditioning of ischemic rat cardiac grafts,”
European Surgical Research, vol. 45, no. 1, pp. 1–8, 2010.
[254] D. Azoulay, M. Del Gaudio, P. Andreani et al., “Eﬀects of 10
minutes of ischemic preconditioning of the cadaveric liver on
the graft’s preservation and function: the Ying and the Yang,”
Annals of Surgery, vol. 242, no. 1, pp. 133–139, 2005.
[255] W. Jassem, S. V. Fuggle, L. Cerundolo, N. D. Heaton, and M.
Rela, “Ischemic preconditioning of cadaver donor livers pro-
tects allografts following transplantation,” Transplantation,
vol. 81, no. 2, pp. 169–174, 2006.
[256] M. S. Marber, J. D. Molkentin, and T. Force, “Developing
small molecules to inhibit kinases unkind to the heart: P38
MAPK as a case in point,” Drug Discovery Today, vol. 7, no. 2,
pp. e123–e127, 2010.
[257] M. C. Genovese, S. B. Cohen, D.Wofsy et al., “A 24-week, ran-
domized, double-blind, placebo-controlled, parallel group
study of the eﬃcacy of oral SCIO-469, a p38 mitogen-
activated protein kinase inhibitor, in patients with active
rheumatoid arthritis,” Journal of Rheumatology, vol. 38, no.
5, pp. 846–854, 2011.
[258] P. Anand, R. Shenoy, J. E. Palmer et al., “Clinical trial of the
p38 MAP kinase inhibitor dilmapimod in neuropathic pain
following nerve injury,” European Journal of Pain, vol. 15, no.
10, pp. 1040–1048, 2011.
[259] D. J. Hausenloy, G. Baxter, R. Bell et al., “Translating
novel strategies for cardioprotection: the Hatter Workshop
Recommendations,” Basic Research in Cardiology, vol. 105,
no. 6, pp. 677–686, 2010.
[260] C. Piot, P. Croisille, P. Staat et al., “Eﬀect of cyclosporine
on reperfusion injury in acute myocardial infarction,” New
England Journal of Medicine, vol. 359, no. 5, pp. 473–481,
2008.
[261] R.W. Jamieson and P. J. Friend, “Organ reperfusion and pres-
ervation,” Frontiers in Bioscience, vol. 13, no. 1, pp. 221–235,
2008.
[262] S. Jacobs, F. Rega, and B. Meyns, “Current preservation tech-
nology and future prospects of thoracic organs—part 2:
heart,”Current Opinion in Organ Transplantation, vol. 15, no.
2, pp. 156–159, 2010.
[263] S. Osaki, K. Ishino, Y. Kotani et al., “Resuscitation of non-
beating donor hearts using continuousmyocardial perfusion:
the importance of controlled initial reperfusion ,” Annals of
Thoracic Surgery, vol. 81, no. 6, pp. 2167–2171, 2006.
